Matrix metalloproteinase (MMP) inhibitors and use methods thereof
By developing highly active and specific hydantoin derivative compounds, especially formulas (I), (II), (III), and (IV), the shortcomings of existing MMP-12 inhibitors in terms of specificity and efficacy have been overcome, enabling effective treatment of a variety of diseases.
Patent Information
- Application Number
- CN201980047375.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-05-15
- Filing Date
- 2019-05-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-05-14
AI Technical Summary
Existing MMP-12 inhibitors are inadequate in terms of specificity, potency, and pharmacological properties, making them difficult to effectively treat a variety of diseases.
Provide highly active and specific hydantoin derivatives, particularly compounds of formulas (I), (II), (III), (IV), and (V), for selective inhibition of macrophage elastase (MMP-12), and develop corresponding pharmaceutical compositions.
These compounds exhibit significant inhibitory effects on MMP-12 and can effectively treat diseases such as asthma, chronic obstructive pulmonary disease, emphysema, acute lung injury, and idiopathic pulmonary fibrosis, demonstrating improved specificity and pharmacological properties.
Smart Images

Figure BDA0002899042150000031 
Figure BDA0002899042150000032 
Figure BDA0002899042150000033
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority under 35 USC §119(e) to U.S. Provisional Patent Application No. 62 / 671,753, filed on May 15, 2018, the disclosure of which is incorporated herein by reference. Background of the Invention
[0004] Matrix metalloproteinases (MMPs) are a superfamily of proteases that are important for the degradation of most extracellular matrix proteins during organ formation, growth, and normal tissue renewal. MMPs are also thought to be important in the uncontrolled breakdown of connective tissue, which is associated with several diseases, such as rheumatoid arthritis, osteoarthritis, gastric ulcers, asthma, emphysema, and tumor metastasis. Therefore, inhibition of one or more MMPs may be beneficial in these diseases.
[0005] Human macrophage elastase (MMP-12) is a specific MMP. MMP-12 has all the characteristics of other MMPs, but is preferentially produced by macrophages that infiltrate damaged or remodeled tissues and degrade the extracellular matrix. For example, elevated levels of MMP-12 have been observed during episodes of emphysema. In addition, MMP-12 knockout mouse models did not develop emphysema after prolonged exposure to cigarette smoke (Hautamkai et al. Science, 1997, 277: 2002-2004). These data suggest that MMP-12 plays a role in the disease progression of emphysema. Based on studies of MMP-12-deficient asthma models, it was proposed that MMP-12 is involved in the development of chronic asthma (Warner et al. Am J Pathol. 2004; 165(6): 1921–1930). In a Fas-induced acute lung injury model, MMP12-deficient mice were protected from developing pulmonary fibrosis (Matute-Bello et al. Am J Respir Cell Mol Biol. 2007;37(2):210–221). In models of pulmonary and liver fibrosis caused by Schistosoma mansoni infection, MMP-12 has fibrogenic activity in the lung and liver (Madala et al. J Immunol 2010;184:3955-3963). Because BALF levels of MMP-12-generated type IV collagen fragments are elevated in IPF patients, MMP-12 may also contribute to IPF pathogenesis by cleaving extracellular matrix (ECM) proteins (Sand et al. PLoS One, 2013;8:e84934), and human MMP-12 can cleave many human ECM proteins in vitro (Owen et al. J Leukoc Biol, 1999;65:137–150). Taken together, these results suggest that MMP-12 inhibitors may be useful in the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, asthma, acute lung injury, IPF, liver fibrosis, and nonalcoholic steatohepatitis (NASH).
[0006] MMP-12 is secreted by alveolar macrophages of smokers (Shapiro et al. Journal of Biological Chemistry, 1993, 268:23824), in foam cells of atherosclerosis (Matsumoto et al. Am. J. Pathol. 1998, 153:109), and in a rat model of nephritis (Kaneko et al. J. Immunol., 2003, 170:3377). MMP-12 also plays a role in coronary artery disease (Jormsjo et al., Circulation Research, 2000, 86: 998). MMP-12 is known to be upregulated in patients with inflammatory bowel disease (IBD) and in T cell-mediated colitis models and contributes to epithelial degradation, and MMP-12- / - mice are protected from TNBS-induced colitis (Pender et al. Ann NY Acad Sci. 2006, 1072: 386-8.). Epithelial and stromal MMP-12, as well as MMP-3 and MMP-7, are upregulated in the pouch mucosa of pediatric UC, suggesting that the chronic expression of MMPs in pediatric UC pouches shares common features with IBD ( et al., World J Gastroenterol. 2012, 18(30): 4028-36). Taken together, these observations suggest that MMP-12 may be a therapeutic target for these diseases.
[0007] In view of the involvement of MMP-12 in various diseases, attempts have been made to prepare inhibitors of MMP-12. Many MMP-12 inhibitors are known (e.g., see International Patent Application Publication WO 00 / 40577; European Patent Application Publication EP 1 288 199 A1; U.S. Patent No. 6,352,9761 and U.S. Patent Application No. 2004 / 0072871; and European Patent Application Publication EP1394159).
[0008] A specific class of MMP inhibitors that have been disclosed is hydantoin derivatives. For example, International Patent Application Publication WO02 / 096426 describes hydantoin derivatives of the following general formula:
[0009] It is disclosed as having MMP inhibitor activity, especially against tumor necrosis factor-α converting enzyme (TACE) and aggrecanase. The disclosed structure of these derivatives is characterized by a spirocyclic link between the hydantoin ring and its side chain. U.S. Patent Application Publication No. 2004 / 0067996 and International Patent Application Publication No. WO2004 / 108086 describe similar hydantoin derivatives of the following general formula:
[0010] Also known as MMP inhibitors, especially for TACE and aggrecanase.
[0011] International patent application publication WO 02 / 074752 describes the synthesis of MMP inhibitors, and international patent application publication WO 2004 / 020415 discloses MMP-12 inhibitors, which are hydantoin derivatives having the following general formula:
[0012] Some of the disclosed compounds exhibit MMP inhibitory activity, including MMP-12 inhibitory activity.
[0013] Recently, MMP-12 inhibitors were described in U.S. Pat. No. 7,179,831, which are hydantoin derivatives of the following general formula:
[0014]
[0015] Hydantoin derivatives are a class of useful MMP inhibitors. However, there is a need in the art to identify hydantoin derivatives with improved specificity, potency and pharmacological properties. Summary of the invention
[0016] The present application meets this need by providing hydantoin derivatives having high activity and specificity for MMPs, in particular macrophage elastase (MMP-12).
[0017] In one general aspect, the present application relates to compounds of formula (I):
[0018]
[0019] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0020] in:
[0021] Ring B is an optionally substituted furanyl group;
[0022] Ring C is optionally substituted aryl or optionally substituted heteroaryl;
[0023] Ring D is optionally substituted aryl or optionally substituted heteroaryl;
[0024] X, Y and Z are each independently selected from the group consisting of CH2, O, NR x and S(O) q , where R x is hydrogen or alkyl;
[0025] R1 is hydrogen or alkyl;
[0026] R4 is hydrogen or alkyl;
[0027] R5 is hydrogen; and
[0028] q is 0, 1, or 2,
[0029] Restriction: When ring D is phenyl, at least one of the following is true:
[0030] (i) R1 is an alkyl group;
[0031] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0032] (iii) Ring C is not unsubstituted phenyl.
[0033] In one embodiment, the present application relates to a compound of formula (II):
[0034]
[0035] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0036] in:
[0037] Ring B is an optionally substituted furanyl group;
[0038] Ring C is aryl or heteroaryl;
[0039] Ring D is aryl or heteroaryl;
[0040] X, Y and Z are each independently selected from the group consisting of CH2, O, NR x and S(O) q , where R x is hydrogen or alkyl;
[0041] R1 is hydrogen or alkyl;
[0042] Each R2 is independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, haloalkyl, alkoxy, alkylthio, amino, amido, alkylamino, aminoalkyl, cyano, hydroxyalkyl, -(CH2) p C(O)OR6 and -(CH2) p OC(O)R6;
[0043] Each R3 is independently selected from the group consisting of hydrogen, alkyl and halogen;
[0044] R4 is hydrogen or alkyl;
[0045] R5 is hydrogen;
[0046] Each R6 is independently selected from the group consisting of hydrogen and alkyl, wherein the alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of amino, hydroxy, halogen, and alkoxy;
[0047] m is 1, 2, 3 or 4;
[0048] n is 1, 2, 3, 4 or 5;
[0049] p is 0, 1, 2, 3, 4 or 5; and
[0050] q is 0, 1, or 2,
[0051] Restriction: When ring D is phenyl, at least one of the following is true:
[0052] (i) R1 is an alkyl group;
[0053] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0054] (iii) Ring C is not unsubstituted phenyl.
[0055] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein ring C is phenyl.
[0056] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein ring D is pyridyl or pyridyl N-oxide.
[0057] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R4 is hydrogen.
[0058] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R1 is an alkyl group.
[0059] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein X is S and Z is CH2.
[0060] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein X is S, Y is O, and Z is CH2.
[0061] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein n is 1; and R2 is alkyl, alkoxy, hydroxy, hydroxyalkyl or amide.
[0062] In one embodiment, the present application relates to a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein n is 1; and R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0063] In one embodiment, the present application relates to a compound of formula (III):
[0064]
[0065] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0066] in:
[0067] R1 is hydrogen or C 1-4 alkyl;
[0068] X is S;
[0069] Y is O, CH2, NH or N(CH3);
[0070] Each R2 is independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, amide, and hydroxyalkyl;
[0071] Each R3 is hydrogen, alkyl or halogen;
[0072] Ring D is phenyl, pyridyl or pyridyl N-oxide;
[0073] R4 and R5 are each hydrogen;
[0074] R7 is hydrogen or methyl; and
[0075] n is 1 or 2.
[0076] In one embodiment, the present application relates to a compound of formula (IV):
[0077]
[0078] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0079] in:
[0080] R1 is hydrogen or alkyl;
[0081] R2 is selected from the group consisting of alkyl, amide, hydroxy, alkoxy and hydroxyalkyl;
[0082] R4 and R5 are each hydrogen; and
[0083] R7 is methyl or hydrogen.
[0084] In one embodiment, the present application relates to a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0085] In one embodiment, the present application relates to a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R1 is C 1-4 alkyl.
[0086] In one embodiment, the present application relates to a compound of formula (V) or a pharmaceutically acceptable salt thereof:
[0087]
[0088] in:
[0089] R1 is an alkyl group;
[0090] R2 is selected from the group consisting of alkyl, amide, alkoxy, hydroxy and hydroxyalkyl;
[0091] R4 and R5 are each hydrogen; and
[0092] R7 is methyl or hydrogen.
[0093] In one embodiment, the present application relates to a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0094] In one embodiment, the present application relates to a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein R1 is C 1-4 alkyl.
[0095] In one embodiment, the present application relates to a compound selected from the following group: a compound listed in Table 1, or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof.
[0096] In one embodiment, the present application relates to a compound selected from the following group: a compound listed in Table 1, or a pharmaceutically acceptable salt thereof.
[0097] In another general aspect, the present application relates to a pharmaceutical composition comprising a compound of the present application as described herein or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable carrier.
[0098] Other general aspects of the present application relate to methods of inhibiting macrophage elastase (MMP-12) in a subject in need thereof, and methods of treating a disease mediated by macrophage elastase (MMP-12) in a subject in need thereof.
[0099] In one embodiment, the present application relates to a method of inhibiting macrophage elastase (MMP-12) in a subject in need thereof, comprising administering to the subject a compound or pharmaceutical composition of the present application.
[0100] In one embodiment, the present application relates to a method for treating a disease mediated by macrophage elastase (MMP-12) in a subject in need thereof, comprising administering a compound or pharmaceutical composition of the present application to the subject.
[0101] In some embodiments, the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, and idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
[0102] The present application also provides a compound or its tautomer, stereoisomer, pharmaceutically acceptable salt or solvate, or composition, for inhibiting macrophage elastase (MMP-12) or treating a disease mediated by macrophage elastase (MMP-12). In some embodiments, the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, and idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome and nephritis.
[0103] The present application also provides the use of the compound of the present application or its tautomer, stereoisomer, pharmaceutically acceptable salt or solvate, or the composition of the present application, for preparing a drug for inhibiting macrophage elastase (MMP-12) or treating a disease mediated by macrophage elastase (MMP-12). Preferably, the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, and idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome and nephritis.
[0104] In another general aspect, the present application relates to a method for preparing the pharmaceutical composition of the present application, comprising combining the compound of the present application or its tautomer, stereoisomer, pharmaceutically acceptable salt or solvate with at least one pharmaceutically acceptable carrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0105] The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the accompanying drawings.It should be understood that the invention is not limited to the precise embodiments shown in the drawings.
[0106] In the figure:
[0107] Figures 1A-1K Describes the results of a study on the therapeutic efficacy of an MMP-12 inhibitor according to an embodiment of the present application for idiopathic pulmonary fibrosis (IPF) in a bleomycin-induced Sprague-Dawley (SD) rat unilateral pulmonary fibrosis model (as described in Example 3); Figure 1A Hematoxylin and eosin (H&E) stained sections were shown for scoring of bronchiolar and pulmonary arteriolar damage and inflammatory cell infiltration in the fibrotic core and fibrotic plate areas according to the criteria in Tables 3.2 and 3.3 below; Figure 1B The Masson trichrome sections for scoring pulmonary fibrosis according to the criteria described in Table 3.4 below are shown; the histological characteristics of pulmonary fibrosis scoring criteria: Group A: normal, Group B: 1 point, Group C: 2 points, Group D: 3 points, Group E: 4 points, Group F: 5 points, Group G: 6 points, Group H: 7 points, Group I: 8 points; Figure 1CThe bronchial and arteriolar injuries in the fibrotic core of experimental SD rats stained with H&E at a magnification of 200 times are shown; Group A: sham group (Group 1), Group B: model group (Group 2), Group C: FC-4 group (Group 4, 10 mg / kg / day), Group D: FC-4 group (Group 5, 30 mg / kg / day), Group E: FC-4 group (Group 6, 100 mg / kg / day); "a" refers to pulmonary arterioles, and "b" refers to bronchus; Figure 1D Shown are bronchial and arteriolar injuries in the fibrotic border of experimental SD rats at x200 magnification by H&E staining; Group A: sham operation group (Group 1), Group B: model group (Group 2), Group C: FC-4 group (Group 4, 10 mg / kg / day), Group D: FC-4 group (Group 5, 30 mg / kg / day), Group E: FC-4 group (Group 6, 100 mg / kg / day); "a" refers to pulmonary arterioles, "b" refers to bronchus; Figure 1E The bronchial and arteriolar injury scores in the fibrotic core of experimental SD rats are graphically shown; one-way ANOVA: ***p<0.001vs model group; Figure 1F Bronchial and arteriolar injury scores in the fibrotic border are shown; one-way ANOVA: ***p<0.001 vs. model, **p<0.01 vs. model; Figure 1G The histological changes of lung fibrosis in SD rats by Masson pine trichrome staining are shown; Group A: sham operation group (Group 1), Group B: model group (Group 2), Group C: FC-4 group (Group 4, 10 mg / kg / day), Group D: FC-4 group (Group 5, 30 mg / kg / day), Group E: FC-4 group (Group 6, 100 mg / kg / day); Figure 1H The left lung fibrosis scores of experimental SD rats according to the Ashcraft score are graphically shown; one-way ANOVA: **p<0.01 compared with the model group, ***p<0.001 compared with the model group; Fig. 1I The ratio of the left lung fibrosis score of the experimental animal SD rats according to the Ashcraft score is shown graphically. Two-way ANOVA: ***p<0.001 compared with the model group; Figure 1JFigure 2 shows the histological changes of collagen deposition, MMP-12 expression, TGF-β1 expression and elastin expression in experimental SD rats by H&E staining at a magnification of x200; (I) shows collagen I deposited on the alveolar wall in the fibrotic core, as indicated by the arrow, (II) shows collagen IV deposited in the fibrotic core, as indicated by the arrow, (III) shows the expression of MMP-12 in the fibrotic core, the arrow indicates the expression of MMP-12 on the alveolar wall and on inflammatory cells in the fibrotic core, (IV) shows the fibrotic core. (I)-(V) shows the expression of TGF-β1 in the core, the arrow indicates the expression of TGF-β1 in inflammatory cells in the fibrotic core, (V) shows the expression of elastin in the fibrotic core, the arrow indicates the expression of elastin on the alveolar wall in the fibrotic core; for each of (I)-(V), Group A: sham group (Group 1), Group B: model group (Group 2), Group C: FC-4 group (Group 4, 10 mg / kg / day), Group D: FC-4 group (Group 5, 30 mg / kg / day), Group E: FC-4 group (Group 6, 100 mg / kg / day); Figure 1K The positive staining scores of collagen I deposition, collagen IV deposition, MMP-12 expression, TGF-β1 expression and elastin expression of experimental SD rats are shown; (I)-(V) correspond to Figure 1J The groups AF of each of (I)-(V) shown in FIG. Figure 1J Groups described in A to F; #p<0.05 compared with the model group; ##p<0.01 compared with the model group; ###p<0.001 compared with the model group; **p<0.01 compared with the sham operation group; ***p<0.001 compared with the sham operation group; and
[0108] Figures 2A-2H Describes the results of the study on the effect of the MMP-12 inhibitor described in Example 4 on the SD rat renal fibrosis model of unilateral ureteral occlusion (UUO); Figure 2A The changes in serum BUN at 2 weeks compared with pre-operative (pre-OP) levels in each experimental SD rat group are shown; Figure 2B Shown are the changes in serum creatine at 2 weeks in each experimental SD rat group compared with before surgery (pre-OP); Figure 2C Histological images of H&E-stained kidneys at 200x magnification are shown; Group A: right kidney as normal control, Group B: vehicle-treated animals, Group C: FC-4-treated animals (2 mg / kg / day), Group D: FC-4-treated animals (6 mg / kg / day), Group E: FC-4-treated animals (20 mg / kg / day); Figure 2DThe tubular injury score (I) and renal interstitial inflammation score (II) of each experimental SD rat group are shown. T test in (I): ***p<0.05 compared with the model group, ***p<0.001 compared with the model group, ##p<0.01 compared with FC-4 (2 mg / kg / day), T test in (II): **p<0.05 compared with the model group, ***p<0.001 compared with the model group, ##p<0.01 compared with FC-4 (6 mg / kg / day), $$p<0.001 compared with FC-4 (2 mg / kg / day); Figure 2E Histological images of Masson Trichrome staining in the kidney at 200x magnification are shown. Groups AH correspond to Figure 2C Group AH described in; Figure 2F The interstitial fibrosis score of renal cortical interstitial fibrosis is shown; T test: **p<0.01 compared with the model group, ***p<0.05 compared with the model group, #p<0.05 compared with FC-4 (2 mg / kg / day); Figure 2G Shows collagen I deposition (I) and collagen IV deposition (II) in the left renal cortical area at 200x magnification by IHC staining; panels AH correspond to Figure 2C Group AH described in; Figure 2H Shown through Figure 2G Positive staining for collagen I deposition (%) (I) and positive staining for collagen IV deposition (%) (II) in the left renal cortical area determined by IHC staining; One-way ANOVA: ***p<0.001 relative to normal control; T test: #p<0.05 compared with the model group, ##p<0.01 compared with the model group, ###p<0.001 compared with the model group. DETAILED DESCRIPTION
[0109] Various publications, articles, and patents are cited or described throughout the specification; each of these references is incorporated herein by reference in its entirety. Discussions of documents, statutes, materials, devices, articles, etc., have been included in this specification to provide a background for the present invention. Such discussion does not imply that all or any of these issues constitute part of the prior art for any invention disclosed or claimed.
[0110] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Otherwise, certain terms used herein have the meanings set forth in the specification. All patents, published patent applications, and publications cited herein are incorporated herein by reference as if fully set forth herein.
[0111] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0112] Unless otherwise indicated, the term "at least" preceding a series of elements should be understood to refer to each element in the series. Using only routine experimentation, those skilled in the art will recognize or be able to ascertain many equivalents to the specific embodiments of the invention described herein. The present invention is intended to encompass such equivalents.
[0113] Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comprise" and variations such as "including" and "comprising" will be understood to imply the inclusion of the stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps. When used herein, the term "comprise" may be replaced with the terms "including" or "comprising", or, at times when used herein, with the term "having".
[0114] As used herein, "consisting of" excludes any element, step, or ingredient not specified in the claim elements. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. Whenever any of the above terms "comprising," "including," "including," and "having" are used in the context of an aspect or embodiment of the present application, the terms "consisting of" or "consisting essentially of" may be used to modify the scope of the present disclosure.
[0115] As used herein, the connection term "and / or" between multiple listed elements should be understood to cover both individual and combined options. For example, where two elements are connected by "and / or", the first option refers to the first element being applicable without the second element. The second option refers to the second element being applicable without the first element. The third option refers to the first and second elements being applicable together. Any of these options should be understood to fall within this meaning and therefore satisfy the requirements of the term "and / or" as used herein. More than one of the options that apply simultaneously should also be understood to be within its meaning and therefore satisfy the requirements of the term "and / or".
[0116] Unless otherwise indicated, any numerical value, such as the concentration or concentration range described herein, should be understood as modified by the term "about" in any case. Therefore, numerical values generally include ± 10% of the value. For example, the "10 times" includes 9 times and 11 times. As used herein, unless the context clearly indicates otherwise, the use of numerical ranges explicitly includes all possible subranges, all individual numerical values within the range, including integers within the range and fractions of the value.
[0117] As used herein, "subject" refers to any animal, preferably a mammal, and most preferably a human, that is to be or has been treated by a method according to an embodiment of the present application. As used herein, the term "mammal" encompasses any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, non-human primates (NHPs), such as monkeys or apes, humans, etc., more preferably humans.
[0118] As used herein, the phrase "pharmaceutically acceptable salts" refers to those salts of the compounds of interest that are safe and effective for topical use in mammals and that possess the desired biological activity. Pharmaceutically acceptable salts include salts of acidic or basic groups present in the particular compound. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloric acid, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, superphosphate, isonicotinic acid, carbonate, bicarbonate, acetate, lactate, salicylate, citrate, tartrate, propionate, butyrate, pyruvate, oxalate, malonate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, sucrose salt, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoic acid)) salt. Certain compounds used in the present application can form pharmaceutically acceptable salts with various amino acids. Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, bismuth, and diethanolamine salts. For a review of pharmaceutically acceptable salts, see Berge et al., 66 J. Pharm. Sci., 1-19 (1977), incorporated herein by reference.
[0119] As used herein, the term "alkyl" refers to a saturated, monovalent, straight or branched hydrocarbon chain. The alkyl group may be unsubstituted or substituted with one or more suitable substituents. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl) and pentyl (e.g., n-pentyl, isopentyl, neopentyl), etc. The alkyl group may have a specified number of carbon atoms. When a number appears in a subscript after the symbol "C", the subscript more clearly defines the number of carbon atoms that a particular alkyl group may contain. For example, "C1 to C 10 Alkyl" or "C 1-10 The term "alkyl" is intended to include C1, C2, C3, C4, C5, C6, C7, C8, C9 and C10 In addition, for example, "C1 to C6 alkyl" or "C 1-6 "Alkyl" means an alkyl group having 1 to 6 carbon atoms.
[0120] As used herein, the term "alkoxy" refers to -O-alkyl, wherein alkyl is as defined above. The alkoxy group is attached to the parent molecule through an oxygen atom. The alkoxy group may have a specified number of carbon atoms. For example, "C1 to C 10 Alkoxy" or "C 1-10 The term "alkoxy" is intended to include C1, C2, C3, C4, C5, C6, C7, C8, C9 and C 10 In addition, for example, "C1 to C6 alkoxy" or "C 1-6 "Alkoxy" means an alkoxy group having 1-6 carbon atoms. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy, isopropoxy), butoxy (e.g., n-butoxy, isobutoxy, tert-butoxy), pentoxy (e.g., n-pentoxy, isopentyl, neopentyl), and the like. The alkoxy group may be unsubstituted or substituted with one or more suitable substituents. Similarly, "alkylthio" or "thioalkoxy" means an alkyl group as defined above connected by a sulfur bridge, such as -S-methyl, -S-ethyl, and the like. Representative examples of alkylthio include, but are not limited to, -SCH3, -SCH2CH3, and the like.
[0121] As used herein, the term "halogen" refers to fluorine, chlorine, bromine or iodine. Accordingly, the term "halo" refers to fluoro, chloro, bromo and iodo.
[0122] "Haloalkyl" is intended to include branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more halogen atoms. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
[0123] The terms “hydroxy” and “hydroxyl” are used interchangeably to refer to the –OH group.
[0124] The term "carboxyl" refers to -COOH.
[0125] The term "cyano" refers to -CN.
[0126] The term "amino" refers to -NH2. The term "alkylamino" refers to an amino group in which one or both of the hydrogen atoms attached to the nitrogen are replaced by an alkyl group. For example, alkylamino groups include: methylamino (-NHCH3), dimethylamino (-N(CH3)2), -NHCH2CH3, etc.
[0127] As used herein, the term "aminoalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more amino groups. 1-4 "Aminoalkyl" is intended to include C1, C2, C3, and C4 alkyl groups substituted with one or more amino groups. Representative examples of aminoalkyl groups include, but are not limited to, -CH2NH2, -CH2CH2NH2, and -CH2CH(NH2)CH3.
[0128] As used herein, "amide" refers to -C(O)N(R)2, wherein each R is independently alkyl or hydrogen. Examples of amides include, but are not limited to: -C(O)NH2, -C(O)NHCH3, and -C(O)N(CH3)2.
[0129] The terms "hydroxyalkyl" and "hydroxyalkyl" are used interchangeably and refer to an alkyl group substituted with one or more hydroxyl groups. The alkyl group can be a branched or straight chain aliphatic hydrocarbon. Examples of hydroxyalkyl groups include, but are not limited to, hydroxymethyl (-CH2OH), hydroxyethyl (-CH2CH2OH), and the like.
[0130] As used herein, the term "aryl" is a group containing any carbon-based aromatic group, including but not limited to: phenyl, naphthyl, anthracenyl, phenanthrenyl, etc. Aryl moieties are well known and described, for example, in Lewis, RJ, Hawley's Condensed Chemical Dictionary, 13th edition, John Wiley & Sons, Inc., New York (1997). Aryl may be substituted or unsubstituted by one or more suitable substituents. Aryl may be a monocyclic structure (i.e., monocyclic) or a ring structure (i.e., polycyclic) comprising multiple fused ring structures. Preferably, aryl is a monocyclic aryl, such as phenyl.
[0131] As used herein, the term "heteroaryl" includes stable monocyclic and polycyclic aromatic hydrocarbons containing at least one heteroatom ring member, such as sulfur, oxygen or nitrogen. Heteroaryl can be monocyclic or polycyclic (e.g., bicyclic or tricyclic). Each ring of the heteroaryl containing heteroatoms can contain one or two oxygen or sulfur atoms and / or 1-4 nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less, and each ring has at least one carbon atom. For bicyclic heteroaryl, the fused ring that makes the bicyclic group complete can contain only carbon atoms and can be saturated, partially saturated or unsaturated. Polycyclic heteroaryl (such as bicyclic or tricyclic heteroaryl) must include at least one completely aromatic ring but the other fused ring can be aromatic or non-aromatic. Heteroaryl can be connected on any available nitrogen or carbon atom of any ring of heteroaryl. Preferably, the term "heteroaryl" refers to a 5- or 6-membered monocyclic group and a 9- or 10-membered bicyclic group having at least one heteroatom (O, S or N) in at least one ring, wherein the heteroatom-containing ring preferably has 1, 2 or 3 heteroatoms, more preferably 1 or 2 heteroatoms selected from O, S and / or N. The heteroaryl group may be unsubstituted or substituted with one or more suitable substituents. The nitrogen heteroatom of the heteroaryl group may be substituted or unsubstituted. The nitrogen and sulfur heteroatoms of the heteroaryl group may be optionally oxidized (i.e., N→O and S(O) r , where r is 0, 1 or 2).
[0132] Exemplary monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl. Exemplary bicyclic heteroaryl groups include, but are not limited to, indolyl, benzothiazolyl, benzodioxazolyl, benzoxazolyl, benzothienyl, quinolyl, tetrahydroisoquinolyl, isoquinolyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridinyl, furopyridinyl, dihydroisoindolyl, and tetrahydroquinolyl.
[0133] In accordance with the conventions used in the art, the structural formulas herein are used:
[0134]
[0135] A bond that describes the point of attachment of a moiety or substituent to a core or backbone structure.
[0136] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.
[0137] As used herein, the term "substituted" means that at least one hydrogen atom is replaced by a non-hydrogen group, as long as all normal valencies are maintained and the substitution results in a stable compound. When a particular group is "substituted", the group may have one or more substituents independently selected from the list of substituents, preferably 1 to 5 substituents, more preferably 1 to 3 substituents, and most preferably 1 to 2 substituents. When used in reference to substituents, the term "independently" means that when there may be multiple such substituents, these substituents may be the same or different from each other. Examples of suitable substituents include, but are not limited to: alkyl, halogen, alkoxy, amide, alkylthio, amino, alkylamino, aminoalkyl, hydroxyalkyl, hydroxy, carboxyl, etc., for example C 1-4 Alkyl, C 1-3 Alkoxy, -OH, -COOH, -F, -Cl, -C(O)NHCH3, -C(O)N(CH3)2.
[0138] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown as substituted with 0-3 R groups, then the group may be optionally substituted with up to three R groups, and R is selected independently of its definition at each occurrence.
[0139] The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur. For example, "optionally substituted aryl" means that substituents may but need not be present, and that the description includes instances where the aryl is substituted with suitable substituents and where the aryl is not substituted with any substituents.
[0140] Those skilled in the art will recognize that in certain embodiments, the compounds of the present application may have one or more asymmetric carbon atoms in their structure. As used herein, any chemical formula that is shown only as a solid line and not represented by a solid wedge or a hashed wedge bond or represented in other ways to indicate a specific configuration (e.g., R or S) around one or more atoms contemplates every possible stereoisomer, or a mixture of two or more stereoisomers. In other words, if the stereochemistry of the structure is not specified, the structure is intended to cover all individual stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or a racemic mixture. Diastereomers (or diastereomers) refer to stereoisomers that are not enantiomers, i.e., they are not mirror images, and are produced when two or more stereoisomers of a compound have different configurations at one or more equivalent stereocenters and are not mirror images of each other. Substituents (eg, alkyl, heterocyclyl, etc.) may contain stereogenic centers in the R or S configuration.
[0141] Therefore, stereochemically pure isomeric forms (i.e., single enantiomers or single diastereomers) of the compounds of the present invention, as well as mixtures including racemates thereof, are included within the scope of the present invention. When a specific stereoisomer is specified, this means that the stereoisomer is substantially free of other isomers, i.e., is associated with less than 50%, preferably less than 20%, more preferably less than 5%, particularly less than 2%, and most preferably less than 1% of other stereoisomers. For example, when a compound is, for example, specified as (R), this means that the compound is substantially free of (S) isomers. The compounds of the present application described herein can be used as racemic mixtures, enantiomerically or diastereomerically enriched mixtures, or as enantiomerically or diastereomerically pure single stereoisomers.
[0142] In view of the present disclosure, stereochemically pure isomeric forms can be obtained by techniques known in the art. For example, diastereomers can be separated by physical separation methods such as fractional crystallization and chromatographic techniques, and enantiomers can be separated from each other by selective crystallization of diastereomeric salts with optically active acids or bases or by chiral chromatography. Pure stereoisomers can also be synthesized from appropriate stereochemically pure starting materials or prepared by using stereoselective reactions.
[0143] The compounds of the present application can also form tautomers. The term "tautomer" refers to the interchangeable form of a particular compound structure and the compound in which the position of hydrogen atoms and electrons can change. Tautomers are structural isomers of compounds that are prone to mutual conversion, usually resulting in the relocation of protons (hydrogen). Therefore, by the movement of π electrons and an atom (usually hydrogen), the two structures can be in equilibrium. All tautomeric forms of the compounds of the present application and mixtures of tautomers are included within the scope of the present application.
[0144] The compounds of the present application may exist in solvated and non-solvated forms. The term "solvate" refers to the physical association of the compounds of the present application with one or more solvent molecules, for example, through hydrogen bonds. The solvent molecules in the solvate may exist in a regular arrangement and / or a disordered arrangement. The solvate may contain stoichiometric or non-stoichiometric solvent molecules. "Solvate" includes solution phases and separable solvates. The compounds of the present application may form solvates with water (i.e., hydrates) or common organic solvents. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Solvation methods are well known in the art.
[0145] Also included within the scope of the present application are all isotopes of atoms present in the compounds of the present application. Isotopes include those atoms having the same atomic number but different mass numbers. As a general example and not limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include 13 C and 14 C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by techniques analogous to those described herein, by substituting an appropriate isotopically-labeled reagent for the non-labeled reagent otherwise employed.
[0146] As used herein, the name of a compound is intended to encompass all possible existing isomeric forms (eg, optical isomers, enantiomers, diastereomers, racemates or racemic mixtures), tautomers, and pharmaceutically acceptable salts of that compound.
[0147] Compound
[0148] In general, the present application relates to compounds of formula (I):
[0149]
[0150] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0151] in:
[0152] Ring B is an optionally substituted furanyl group;
[0153] Ring C is optionally substituted aryl or optionally substituted heteroaryl;
[0154] Ring D is optionally substituted aryl or optionally substituted heteroaryl;
[0155] X, Y and Z are each independently selected from the group consisting of CH2, O, NR x and S(O) q , where R x is hydrogen or alkyl;
[0156] R1 is hydrogen or alkyl;
[0157] R4 is hydrogen or alkyl;
[0158] R5 is hydrogen; and
[0159] q is 0, 1, or 2,
[0160] Restriction: When the D ring is phenyl, at least one of the following is true:
[0161] (i) R1 is an alkyl group;
[0162] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0163] (iii) Ring C is not unsubstituted phenyl.
[0164] In one embodiment, a compound of formula (II) is provided:
[0165]
[0166] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0167] in:
[0168] Ring B is an optionally substituted furanyl group;
[0169] Ring C is aryl or heteroaryl;
[0170] Ring D is aryl or heteroaryl;
[0171] X, Y and Z are each independently selected from the group consisting of O, CH2, NR x and S(O) q , where R x is hydrogen or alkyl;
[0172] R1 is hydrogen or alkyl;
[0173] Each R2 is independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, haloalkyl, alkoxy, alkylthio, amino, amido, alkylamino, aminoalkyl, cyano, hydroxyalkyl, -(CH2) pC(O)OR6 and -(CH2) p OC(O)R6;
[0174] Each R3 is independently selected from the group consisting of hydrogen, alkyl and halogen;
[0175] R4 is hydrogen or alkyl;
[0176] R5 is hydrogen;
[0177] Each R6 is independently selected from the group consisting of hydrogen and alkyl, wherein the alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of amino, hydroxy, halogen, and alkoxy;
[0178] m is 1, 2, 3 or 4;
[0179] n is 1, 2, 3, 4 or 5;
[0180] p is 0, 1, 2, 3, 4 or 5; and
[0181] q is 0, 1, or 2,
[0182] Restriction: When the D ring is phenyl, at least one of the following is true:
[0183] (i) R1 is an alkyl group;
[0184] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0185] (iii) Ring C is not unsubstituted phenyl.
[0186] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring C is an optionally substituted aryl group, preferably an optionally substituted phenyl group.
[0187] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring C is an optionally substituted heteroaryl, preferably an optionally substituted pyridinyl.
[0188] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein m is 1, and R3 is independently hydrogen, alkyl or halogen, preferably hydrogen, -CH3, -F or -Cl, more preferably hydrogen.
[0189] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring C is phenyl, m is 1, and R3 is hydrogen.
[0190] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is an optionally substituted aryl group, preferably an optionally substituted phenyl group. In such embodiments where ring D is a phenyl group, at least one of the following conditions is satisfied: (i) R1 is an alkyl group; (ii) R2 is not methoxy, chloro or trifluoromethyl; and / or (iii) ring C is not an unsubstituted phenyl group.
[0191] In one embodiment, provided is a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein ring D is an optionally substituted heteroaryl.
[0192] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is optionally substituted by 1, 2, 3, 4 or 5 substituents, preferably substituted by 1 or 2 substituents, and the substituents are independently selected from the following groups: alkyl, halogen, haloalkyl, alkoxy, alkylthio, amino, amide, alkylamino, aminoalkyl, cyano, hydroxyalkyl, -(CH2) p C(O)OR6 and -(CH2) p OC(O)R6, wherein p is 0, 1, 2, 3, 4 or 5. The substituent, if present, may be attached at any position of ring D. Preferably, ring D is substituted with one substituent.
[0193] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is a monocyclic aryl or monocyclic heteroaryl substituted by a substituent at the meta position relative to the bond to variable Z, preferably a phenyl or pyridyl substituted at the meta position. For ring D, particularly preferred substituents include: methyl (-CH3), amide (-C(O)NH2), methoxy (-OCH3), hydroxyl (-OH) and hydroxymethyl (-CH2OH).
[0194] In a particular embodiment, Ring D is phenyl.
[0195] In another specific embodiment, Ring D is pyridinyl.
[0196] In another specific embodiment, Ring D is pyridinyl N-oxide.
[0197] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 and R2 is C 1-4Alkoxy (e.g., -OCH3, -OCH2CH2CH3, -OCH2CH3, -OCH(CH3)2, -OCH2CH(CH3)2), C 1-4 Preferably, R2 is -CH3, -C(O)NH2, -CH2OH, -OCH3 or OH.
[0198] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is:
[0199]
[0200] According to an embodiment of the present application, the chiral carbon atom of the hydantoin moiety may be unsubstituted (i.e., R1 is hydrogen) or substituted. When substituted, the R1 substituent is preferably an alkyl group. Preferred alkyl groups that replace the chiral carbon atom of the hydantoin moiety include C 1-4 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like.
[0201] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or -CH2CH(CH3)2.
[0202] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen.
[0203] The nitrogen atom of the hydantoin moiety may also be substituted. According to an embodiment of the present application, R4 and R5 are each independently hydrogen or alkyl. Preferred alkyl groups include methyl.
[0204] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 is hydrogen or -CH3, and R5 is -CH3.
[0205] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 and R5 are both hydrogen.
[0206] According to the embodiment of the present application, X, Y and Z are each independently selected from the following groups: O, NR x , CH2 and S(O) q , where q is 0, 1, or 2, and R x is hydrogen or alkyl. Therefore, the linking groups X, Y and Z are each independently selected from: O, S, S(O), SO2, NH, N-alkyl and CH2. Preferably, X, Y and Z are each independently selected from: S, S(O), S(O)2, CH2 and O, more preferably S, CH2 and O.
[0207] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein Z is CH2.
[0208] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S.
[0209] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S; Y is O, CH2, NH or NH(CH3); and Z is CH2.
[0210] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is O, Y is O, and Z is CH2.
[0211] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S, Y is S, and Z is CH2.
[0212] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is O, Y is S, and Z is CH2.
[0213] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S, Y is O, and Z is CH2.
[0214] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein Z is O, Y is CH2, and X is S.
[0215] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein Z is S, Y is CH2, and X is O.
[0216] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S(O), Y is O, and Z is CH2.
[0217] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S(O)2, Y is O, and Z is CH2.
[0218] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S, Y is NH, and Z is CH2.
[0219] In one embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S, Y is N(CH3), and Z is CH2.
[0220] In a preferred embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein one of X and Y is S and the other is O.
[0221] In a more preferred embodiment, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is O.
[0222] According to an embodiment of the application, ring B is an optionally substituted furanyl. Any position or regioisomer of the furanyl ring can be used, which means that the hydantoin moiety and the X linking group can be connected to the furanyl on any substitutable carbon atom on the furanyl ring. For example, relative to the oxygen heteroatom of the furanyl ring, the hydantoin moiety and the X linking group can be connected to the furanyl ring with a 2,3-substitution pattern, a 2,4-substitution pattern, a 2,5-substitution pattern, a 3,4-substitution pattern, etc.
[0223] In some embodiments, a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring B (i.e., furanyl ring) is substituted. Ring B (i.e., furanyl ring) can be substituted on any substitutable carbon atom of the furanyl ring. For example, ring B can be substituted by an alkyl group (e.g., a methyl group).
[0224] In some embodiments, provided is a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein ring B is an unsubstituted furanyl ring.
[0225] In some embodiments, provided is a compound of formula (II) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein Ring B is furanyl substituted with -CH3.
[0226] In one embodiment, a compound of formula (III) is provided:
[0227]
[0228] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0229] Wherein, R7 is hydrogen or methyl; the remaining variable groups are as defined above for the compound of formula (II).
[0230] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R3 is hydrogen, alkyl or halogen, preferably hydrogen, -CH3, -F or -Cl, more preferably hydrogen.
[0231] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is an optionally substituted phenyl, provided that (i) R1 is an alkyl group; (ii) R2 is not methoxy, chloro or trifluoromethyl; and / or (iii) ring C is not an unsubstituted phenyl group.
[0232] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is an optionally substituted heteroaryl.
[0233] In one embodiment, provided is a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, wherein ring D is an optionally substituted pyridinyl or pyridinyl N-oxide.
[0234] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is optionally substituted with 1, 2, 3, 4 or 5 substituents, preferably substituted with 1 or 2 substituents, the substituents being independently selected from the group consisting of alkyl, halogen, haloalkyl, alkoxy, alkylthio, amino, amide, alkylamino, aminoalkyl, cyano, hydroxyalkyl, -(CH2) pC(O)OR6 and -(CH2) p OC(O)R6, wherein p is 0, 1, 2, 3, 4 or 5. If present, the substituent may be attached at any position of ring D. Preferably, ring D is substituted with one substituent (ie, n is 1).
[0235] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is a monocyclic aryl or monocyclic heteroaryl substituted by a substituent at the meta position relative to the bond to variable Z, preferably a phenyl or pyridyl substituted at the meta position. For ring D, particularly preferred substituents include: methyl (-CH3), amide (-C(O)NH2), methoxy (-OCH3), hydroxyl (-OH) and hydroxymethyl (-CH2OH).
[0236] In a particular embodiment, Ring D is phenyl.
[0237] In another specific embodiment, Ring D is pyridinyl.
[0238] In another specific embodiment, Ring D is pyridinyl N-oxide.
[0239] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 and R2 is C 1-4 Alkoxy (e.g., -OCH3, -OCH2CH2CH3, -OCH2CH3, OCH(CH3)2, -OCH2CH(CH3)2), C 1-4 Preferably, R2 is -CH3, -C(O)NH2, -CH2OH, -OCH3 or OH.
[0240] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein ring D is:
[0241]
[0242] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen or C 1-4 alkyl.
[0243] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or -CH2CH(CH3)2.
[0244] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen.
[0245] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 is hydrogen or -CH3, and R5 is -CH3.
[0246] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 and R5 are both hydrogen.
[0247] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X and Y are each independently selected from the group consisting of: O, NR x , CH2 and S(O) q , where q is 0, 1, or 2, and R x is hydrogen or an alkyl group (eg, methyl).
[0248] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S.
[0249] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S; and Y is O, CH2, NH or NH(CH3).
[0250] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is O and Y is O.
[0251] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is S.
[0252] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is O and Y is S.
[0253] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is O.
[0254] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S(O) and Y is O.
[0255] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S(O)2 and Y is O.
[0256] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is NH.
[0257] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is N(CH3).
[0258] In a preferred embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein one of X and Y is S and the other is O.
[0259] In a more preferred embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein X is S and Y is O.
[0260] In one embodiment, a compound of formula (III) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein:
[0261] R1 is hydrogen or C 1-4 alkyl;
[0262] X is S;
[0263] Y is O, CH2, NH or N(CH3);
[0264] Each R2 is independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, amide, and hydroxyalkyl;
[0265] Each R3 is hydrogen, alkyl or halogen;
[0266] Ring D is phenyl, pyridyl or pyridyl N-oxide;
[0267] R4 and R5 are each hydrogen;
[0268] R7 is hydrogen or methyl; and
[0269] n is 1 or 2.
[0270] In one embodiment, a compound of formula (IV) is provided:
[0271]
[0272] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0273] Wherein, R7 is hydrogen or methyl; the remaining variable groups are as defined above for the compounds of formula (II) or formula (III).
[0274] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R2 is C 1-4 Alkoxy (e.g., -OCH3, -OCH2CH2CH3, -OCH2CH3, -OCH(CH3)2, -OCH2CH(CH3)2), C 1-4 Alkyl (e.g., -CH3, -CH2CH3, -CH2CH(CH3)2), -CH2OH, -OH, -COOH, -C(O)NH2, -C(O)NHCH3, or -CH2OC(O)CH(NH2)CH(CH3)2, -C(O)NH2, -C(O)NHCH3.
[0275] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R2 is -CH3, C 1-4 Preferably, R2 is -CH3, -C(O)NH2, -CH2OH, -OCH3 or OH.
[0276] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is C 1-4 alkyl.
[0277] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen.
[0278] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 is hydrogen or -CH3, and R5 is -CH3.
[0279] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 and R5 are each hydrogen.
[0280] In one embodiment, a compound of formula (IV) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein:
[0281] R1 is hydrogen or alkyl;
[0282] R2 is selected from the group consisting of alkyl, amide, hydroxy, alkoxy and hydroxyalkyl;
[0283] R4 and R5 are each hydrogen; and
[0284] R7 is methyl or hydrogen.
[0285] In one embodiment, a compound of formula (V) is provided:
[0286]
[0287] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0288] Wherein, R7 is hydrogen or methyl; the remaining variable groups are as defined above for the compounds of formula (II) or formula (III).
[0289] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R2 is C 1-4 Alkoxy (e.g., -OCH3, -OCH2CH2CH3, -OCH2CH3, OCH(CH3)2, -OCH2CH(CH3)2), C 1-4 Alkyl (e.g., -CH3, -CH2CH3, -CH2CH(CH3)2), -CH2OH, -OH, -COOH, -C(O)NH2, -C(O)NHCH3, or -CH2OC(O)CH(NH2)CH(CH3)2, -C(O)NH2, -C(O)NHCH3.
[0290] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R2 is -CH3, C 1-4Preferably, R2 is -CH3, -C(O)NH2, -CH2OH, -OCH3 or OH.
[0291] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is C 1-4 alkyl.
[0292] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R1 is hydrogen.
[0293] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 is hydrogen or -CH3, and R5 is -CH3.
[0294] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein R4 and R5 are each hydrogen.
[0295] In one embodiment, a compound of formula (V) or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof is provided, wherein:
[0296] R1 is an alkyl group;
[0297] R2 is selected from the group consisting of alkyl, amide, alkoxy, hydroxy and hydroxyalkyl;
[0298] R4 and R5 are each hydrogen; and
[0299] R7 is methyl or hydrogen.
[0300] Exemplary compounds of the present application include, but are not limited to, the compounds listed in Table 1 below and any tautomers, stereoisomers, pharmaceutically acceptable salts or solvates thereof. 50 The IC value is determined according to the assay method described in Example 1 below. 50 Values are reported as follows: A = less than 10 nM, B = 10 nM to 100 nM, C = 100 nM to 1000 nM, D = greater than 1000 nM.
[0301] Table 1: Exemplary compounds of the present application
[0302]
[0303]
[0304]
[0305]
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312] The compounds of the present application can be prepared by a variety of methods as generally described below and more specifically illustrated by the exemplary embodiments later in this article. For example, the compounds of the present application can be prepared according to any one of the general preparation schemes 1 to 3. Those of ordinary skill in the art will recognize that the general preparation schemes 1 to 3 can be modified according to the exemplary embodiments and common knowledge in the art to obtain the compounds of the present application.
[0313] General preparation protocol 1
[0314]
[0315] 1 R3 is hydrogen, alkyl or halogen; R7 is hydrogen or alkyl; Ring D is an optionally substituted aryl or heteroaryl; X is halogen
[0316] Int-A was added to the LDA solution, and the mixture was stirred at -78 ° C for about 1 hour. Int-B was then added, and the mixture was stirred for another 3 hours. The reaction was quenched and extracted. The organic layer was washed, dried, concentrated in vacuo, and the residue was purified by column chromatography to give Int-C. At 0 ° C, NaH was added to the mixture of Int-C and Int-D, and the mixture was stirred at room temperature overnight. The mixture was then concentrated, HCl was added to adjust the pH to 6, and the mixture was filtered to give Int-E. Int-E was reacted with Int-F1 in the presence of DEAD and triphenylphosphine to give Int-G. Alternatively, Int-E was reacted with Int-F2 in the presence of potassium carbonate to give Int-G. Then, Int-G was reacted with (NH4)2CO3 and potassium cyanide (KCN) in aqueous ethanol overnight. The reaction mixture was evaporated to remove the solvent and then extracted. The organic layer is dried and evaporated, and the residue is purified by column chromatography to give a compound according to an embodiment of the present application.
[0317] General preparation scheme 2 1
[0318]
[0319] 1 R1 is alkyl; R3 is hydrogen, halogen or alkyl; X is halogen; Ring D is optionally substituted aryl or optionally substituted heteroaryl
[0320] Under a nitrogen atmosphere, at 80 ° C, Int-D is stirred in DMSO overnight. The mixture is purified to obtain Int-H. A mixture of Int-H, Int-F2 and potassium carbonate is stirred under heating. The mixture is purified to obtain Int-I, which, after column purification, reacts with triphenylphosphine, TBAB and dilute hydrochloric acid to obtain Int-K. In the presence of sodium hydride, Int-C and Int-K react to obtain Int-G. Then, Int-G is reacted with (NH4)2CO3 and potassium cyanide (KCN) in aqueous ethanol overnight. The reaction mixture is evaporated to remove the solvent and then extracted. The organic layer is dried and evaporated, and the residue is purified by column chromatography to obtain a compound according to an embodiment of the present application.
[0321] General preparation scheme 3 1
[0322]
[0323] 1 R3 is hydrogen, alkyl or halogen; R7 is hydrogen or alkyl; Ring D is an optionally substituted aryl or heteroaryl
[0324] Int-E is reacted with (CF3SO2)2O and TEA, and after purification, Int-L is obtained. To Int-L and Int-M solutions, xantphose, Pd2(dba)3 and Cs2CO3 are added. After the mixture is purified, Int-N is obtained. Then, Int-GN is reacted with (NH4)2CO3 and potassium cyanide (KCN) in ethanol aqueous solution overnight. The reaction mixture is evaporated to remove the solvent, and then extracted. The organic layer is dried and evaporated, and the residue is purified by column chromatography to obtain a compound according to an embodiment of the present application.
[0325] Pharmaceutically acceptable salts of the compounds of the present invention can be synthesized from parent compounds containing acidic or basic moieties by conventional chemical methods. Generally, these salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of a suitable acid or base in water or in an organic solvent, or in a mixture of the two. Examples of suitable organic solvents include, but are not limited to, ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
[0326] Composition
[0327] Another aspect of the present application relates to a pharmaceutical composition comprising a compound of the present application as described herein or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof.
[0328] The composition of the present application may also include a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is nontoxic and should not interfere with the efficacy of the active ingredient. A pharmaceutically acceptable carrier may include one or more excipients, such as adhesives, disintegrants, swelling agents, suspending agents, emulsifiers, wetting agents, lubricants, flavoring agents, sweeteners, preservatives, dyes, solubilizers, and coatings. The exact nature of the carrier or other materials may depend on the route of administration, for example, intramuscular, intradermal, subcutaneous, oral, intravenous, skin, mucosal (e.g., intestinal), intranasal, or intraperitoneal routes. For liquid injection preparations, such as suspensions and solutions, suitable carriers and additives include water, glycols, oils, alcohols, preservatives, colorants, etc. For solid oral preparations, such as powders, capsules, caplets, soft capsules, and tablets, suitable carriers and additives include starch, sugars, diluents, granulators, lubricants, adhesives, disintegrants, etc. For nasal spray / inhalant mixtures, aqueous solutions / suspensions may contain water, glycols, oils, emollients, stabilizers, humectants, preservatives, fragrances, flavoring agents, etc. as suitable carriers and additives.
[0329] The composition of the present invention can be formulated into any material suitable for administration to a subject to promote administration and improve efficacy, including but not limited to oral (enteral) administration and parenteral injection. Parenteral injection includes intravenous injection or infusion, subcutaneous injection, intradermal injection and intramuscular injection. The composition of the application can also be formulated for other routes of administration, including transmucosal, eye, rectum, long-acting implant, sublingual administration, sublingual, bypassing the portal circulation from the oral mucosa, inhalation or intranasal administration.
[0330] In certain embodiments, the composition is formulated for oral administration.
[0331] Another aspect of the present application relates to a method for preparing a pharmaceutical composition, which includes combining the compound of the present application or its tautomer, stereoisomer, pharmaceutically acceptable salt or solvate with at least one pharmaceutically acceptable carrier. In view of the present disclosure, the pharmaceutical composition can be prepared by any method known in the art, and those of ordinary skill in the art will be familiar with this technology for preparing pharmaceutical compositions. For example, the pharmaceutical composition according to the present application can be prepared by mixing the compound of the present application with one or more pharmaceutically acceptable carriers according to conventional drug mixing techniques, and the conventional drug mixing techniques include but are not limited to: conventional mixing, dissolving, granulating, emulsifying, encapsulating, encapsulating or lyophilizing processes.
[0332] How to use
[0333] The present application also provides methods for inhibiting matrix metalloproteinases (MMPs) and treating diseases mediated by MMPs using the compounds and pharmaceutical compositions of the present application.
[0334] Matrix metalloproteinases (MMPs), also known as matrix proteins, are a class of enzymes that are jointly responsible for the degradation of most extracellular matrix proteins during organogenesis, growth, and normal tissue renewal. MMPs are calcium-dependent zinc-containing endopeptidases that belong to a larger family of proteases known as the metzincin superfamily. MMPs are capable of degrading extracellular matrix proteins, but can also process many bioactive molecules and are known to participate in, for example, the cleavage of cell surface receptors, the release of apoptotic ligands, and the inactivation of chemokines / cytokines. MMPs are also believed to play a major role in cell behavior (e.g., cell proliferation, migration (adhesion / dispersion), differentiation, angiogenesis, apoptosis, and host defense). MMPs are inhibited by specific endogenous tissue inhibitors of metalloproteinases (TIMPs), which include four protease inhibitor families: TIMP-1, TIMP-2, TIMP-3, and TIMP-4. Examples of MMPs include, but are not limited to, MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin 1), MMP-7 (matrilysin), MMP-8 (neutrophil collagenase), MMP-9 (gelatinase B), MMP-10 (stromelysin 2), MMP-11 (stromelysin 3), MMP-12 (macrophage elastase), MMP-13 (collagenase 3), MMP-14 (MT1-MMP), etc.
[0335] In a preferred embodiment, the compounds of the present application can inhibit microphage elastase (MMP-12) and / or treat diseases mediated by MMP-12. MMP-12, also known as macrophage metalloelastase (MME) or macrophage elastase (ME), is encoded by the MMP12 gene of the human. In other embodiments, the compounds of the present application can selectively inhibit MMP-12. When used in conjunction with or inhibiting the activity of a specific MMP, the terms "selective", "selective" and "selectively" refer to the extent to which a compound binds or inhibits the activity of a specific MMP greater than the extent to which the compound binds or inhibits the activity of other MMPs. For example, a compound selective for MMP-12 inhibits the activity of MMP-12 to a greater extent than other MMPs (e.g., MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, MMP-14, etc.).
[0336] According to an embodiment of the present application, the compound that is selective for MMP-12 inhibits the activity of MMP-12 by at least about 10 times, 100 times, or 1000 times greater than one or more other MMPs, and preferably inhibits the activity of MMP-12 by at least about 1000 times greater than at least one other MMP (e.g., MMP-1 or MMP-7).
[0337] The present application also provides a method for treating a disease mediated by MMP-12. According to an embodiment of the present invention, a method for treating a disease mediated by MMP-12 comprises administering to a subject a therapeutically effective amount of a compound of the present application or any tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition of the present application.
[0338] As used herein, the terms "treat," "therapeutic," and "therapy" are all intended to refer to improving or reversing at least one measurable physical parameter associated with a disease mediated by MMP-12, which is not necessarily discernible in a subject, but can be discerned in a subject. The terms "treat," "therapeutic," and "therapy" may also refer to causing regression of, preventing progression of, or at least slowing progression of a disease mediated by MMP-12. In a specific embodiment, "treat," "therapeutic," and "therapy" refer to alleviating one or more symptoms associated with a disease mediated by MMP-12, preventing its development or onset, or reducing its duration. In a specific embodiment, "treat," "therapeutic," and "therapy" refer to preventing the recurrence of a disease mediated by MMP-12. In a specific embodiment, "treat," "therapeutic," and "therapy" refer to increasing the survival rate of a subject suffering from a disease mediated by MMP-12. In a specific embodiment, "treat," "therapeutic," and "therapy" refer to eliminating a disease mediated by MMP-12 in a subject.
[0339] As used herein, "therapeutically effective amount" refers to the amount of a composition or compound that elicits a biological or medical response in a tissue system or subject that is sought by a researcher, veterinarian, physician, or other condition, which may include alleviating the symptoms of the disease or condition being treated. The therapeutically effective amount may vary depending on a variety of factors, such as the subject's physical condition, age, weight, health status, etc.; and the specific disease to be treated. In view of this disclosure, a person of ordinary skill in the art can readily determine a therapeutically effective amount.
[0340] In a specific embodiment of the present application, a therapeutically effective amount refers to an amount of the composition or compound of the present application sufficient to inhibit MMP-12 or treat a disease mediated by MMP-12. According to the method of the present application, diseases mediated by MMP-12 that can be treated include, but are not limited to, asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
[0341] Implementation
[0342] Embodiment 1 is a compound of formula (I):
[0343]
[0344] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0345] in:
[0346] Ring B is an optionally substituted furanyl group;
[0347] Ring C is optionally substituted aryl or optionally substituted heteroaryl;
[0348] Ring D is optionally substituted aryl or optionally substituted heteroaryl;
[0349] X, Y and Z are each independently selected from: CH2, O, NR x and S(O) q , where R x is hydrogen or alkyl;
[0350] R1 is hydrogen or alkyl;
[0351] R4 is hydrogen or alkyl;
[0352] R5 is hydrogen; and
[0353] q is 0, 1, or 2,
[0354] Restriction: When ring D is phenyl, at least one of the following is true:
[0355] (i) R1 is an alkyl group;
[0356] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0357] (iii) Ring C is not unsubstituted phenyl.
[0358] Embodiment 2 is a compound of formula (II):
[0359]
[0360] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0361] in:
[0362] Ring B is an optionally substituted furanyl group;
[0363] Ring C is aryl or heteroaryl;
[0364] Ring D is aryl or heteroaryl;
[0365] X, Y and Z are each independently selected from the group consisting of O, CH, NR x and S(O) q , where R x is hydrogen or alkyl;
[0366] R1 is hydrogen or alkyl;
[0367] Each R2 is independently selected from the group consisting of hydrogen, alkyl, halogen, hydroxy, haloalkyl, alkoxy, alkylthio, amino, amido, alkylamino, aminoalkyl, cyano, hydroxyalkyl, -(CH2) p C(O)OR6 and -(CH2) p OC(O)R6;
[0368] Each R3 is independently selected from the group consisting of hydrogen, alkyl and halogen;
[0369] R4 is hydrogen or alkyl;
[0370] R5 is hydrogen;
[0371] Each R6 is independently selected from the group consisting of hydrogen and alkyl, wherein the alkyl is unsubstituted or substituted with one or more groups independently selected from the group consisting of amino, hydroxy, halogen, and alkoxy;
[0372] m is 1, 2, 3 or 4;
[0373] n is 1, 2, 3, 4 or 5;
[0374] p is 0, 1, 2, 3, 4 or 5; and
[0375] q is 0, 1, or 2;
[0376] Restriction: When ring D is phenyl, at least one of the following is true:
[0377] (i) R1 is an alkyl group;
[0378] (ii) R2 is not methoxy, chloro or trifluoromethyl; and
[0379] (iii) Ring C is not unsubstituted phenyl.
[0380] Embodiment 3 is a compound of embodiment 1 or embodiment 2, wherein ring C is phenyl.
[0381] Embodiment 4 is a compound of embodiment 1 or embodiment 2, wherein ring C is pyridinyl.
[0382] Embodiment 5 is a compound of any one of embodiments 2 to 4, wherein R3 is selected from the group consisting of hydrogen, methyl, fluoro and chloro.
[0383] Embodiment 6 is a compound of any one of embodiments 1 to 5, wherein ring D is pyridinyl.
[0384] Embodiment 7 is a compound of any one of embodiments 1 to 5, wherein ring D is phenyl.
[0385] Embodiment 8 is a compound of any one of embodiments 2 to 7, wherein R2 is selected from the group consisting of methyl, -CH2OH, hydroxy, -OC(O)CH(NH2)CH(CH3)2, -COOH, -CH2OC(O)CH(NH2)CH(CH3)2, -C(O)NH2, -C(O)NH(CH3), and C 1-4 Alkoxy.
[0386] Embodiment 9 is a compound of embodiment 8, wherein R2 is selected from the group consisting of -CH2OH, hydroxy, -OC(O)CH(NH2)CH(CH3)2, -COOH, -CH2OC(O)CH(NH2)CH(CH3)2, -C(O)NH2, -C(O)NH(CH3) and C 2-4 Alkoxy.
[0387] Embodiment 10 is a compound of any one of embodiments 2 to 7, wherein R2 is selected from the group consisting of alkyl, amide, hydroxy, alkoxy, and hydroxyalkyl.
[0388] Embodiment 11 is a compound of embodiment 10, wherein n is 1; R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0389] Embodiment 12 is a compound of any one of embodiments 1 to 5, wherein ring D is:
[0390]
[0391] Embodiment 13 is a compound of any one of embodiments 1 to 12, wherein R4 is hydrogen.
[0392] Embodiment 14 is a compound of any one of embodiments 1 to 12, wherein R4 is alkyl.
[0393] Embodiment 15 is a compound of embodiment 14, wherein R4 is methyl.
[0394] Embodiment 16 is a compound of any one of embodiments 1 to 15, wherein R1 is hydrogen.
[0395] Embodiment 17 is a compound of any one of embodiments 1 to 15, wherein R1 is alkyl.
[0396] Embodiment 18 is a compound of embodiment 17, wherein R1 is C 1-4 alkyl.
[0397] Embodiment 19 is a compound of embodiment 18, wherein R1 is -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2 or -CH2CH(CH3)2.
[0398] Embodiment 20 is a compound of any one of embodiments 1 to 19, wherein X is S.
[0399] Embodiment 21 is a compound of any one of embodiments 1 to 20, wherein Z is CH2.
[0400] Embodiment 22 is a compound of any one of embodiments 1 to 19, wherein X is S, Y is O, and Z is CH2.
[0401] Embodiment 23 is a compound of embodiment 2, which is a compound of formula (III):
[0402]
[0403] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0404] in:
[0405] R1 is hydrogen or C 1-4 alkyl;
[0406] X is S;
[0407] Y is O, CH2, NH or N(CH3);
[0408] Each R2 is independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, amide, and hydroxyalkyl;
[0409] Each R3 is hydrogen, alkyl or halogen;
[0410] Ring D is phenyl, pyridyl or pyridyl N-oxide;
[0411] R4 and R5 are each hydrogen;
[0412] R7 is hydrogen or methyl; and
[0413] n is 1 or 2.
[0414] Embodiment 24 is a compound of formula (IV):
[0415]
[0416] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0417] in:
[0418] R1 is hydrogen or alkyl;
[0419] R2 is selected from the group consisting of alkyl, amide, hydroxy, alkoxy and hydroxyalkyl;
[0420] R4 is hydrogen or alkyl;
[0421] R5 is hydrogen; and
[0422] R7 is methyl or hydrogen.
[0423] Embodiment 25 is a compound of embodiment 24, wherein R4 is hydrogen.
[0424] Embodiment 26 is a compound of embodiment 24 or 25, wherein R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0425] Embodiment 27 is a compound of any one of embodiments 24 to 26, wherein R1 is C 1-4 alkyl.
[0426] Embodiment 28 is a compound of formula (V):
[0427]
[0428] or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof,
[0429] in:
[0430] R1 is an alkyl group;
[0431] R2 is selected from the group consisting of alkyl, amide, alkoxy, hydroxyl and
[0432] Hydroxyalkyl;
[0433] R4 is hydrogen or alkyl;
[0434] R5 is hydrogen; and
[0435] R7 is methyl or hydrogen.
[0436] Embodiment 29 is a compound of embodiment 28, wherein R4 is hydrogen.
[0437] Embodiment 30 is a compound of embodiment 28 or embodiment 29, wherein R2 is -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2.
[0438] Embodiment 31 is a compound of any one of embodiments 28-30, wherein R1 is C 1-4 alkyl.
[0439] Embodiment 32 is a compound of any one of embodiments 1 to 31 which is not:
[0440]
[0441]
[0442] Embodiment 33 is a compound selected from the group consisting of a compound in Table 1 or a tautomer, stereoisomer, pharmaceutically acceptable salt or solvate thereof.
[0443] Embodiment 34 is a pharmaceutical composition comprising a compound of any one of embodiments 1-33 and at least one pharmaceutically acceptable carrier.
[0444] Embodiment 35 is a method of inhibiting macrophage elastase (MMP-12) in a subject in need thereof, the method comprising administering the pharmaceutical composition of embodiment 34 to the subject.
[0445] Embodiment 36 is a method of treating a disease mediated by macrophage elastase (MMP-12) in a subject in need thereof, the method comprising administering the pharmaceutical composition of embodiment 34 to the subject.
[0446] Embodiment 37 is the method of embodiment 36, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
[0447] Embodiment 38 is a compound of any one of embodiments 1-33 or a pharmaceutical composition of embodiment 34 for inhibiting macrophage elastase (MMP-12).
[0448] Embodiment 39 is a compound of any one of embodiments 1-33 or a pharmaceutical composition of embodiment 34 for use in treating a disease mediated by macrophage elastase (MMP-12).
[0449] Embodiment 40 is a compound or composition for use in embodiment 39, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
[0450] Embodiment 41 is use of the compound of any one of embodiments 1-33 or the pharmaceutical composition of embodiment 34 in the preparation of a medicament for inhibiting macrophage elastase (MMP-12).
[0451] Embodiment 42 is the use of a compound of any one of embodiments 1-33 or a pharmaceutical composition of embodiment 34 in the preparation of a medicament for treating a disease mediated by macrophage elastase (MMP-12).
[0452] Embodiment 43 is the use of embodiment 42, wherein the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome and nephritis.
[0453] Embodiment 44 is a method for preparing the pharmaceutical composition of embodiment 33, which comprises combining the compound or a pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable carrier.
[0454] Example
[0455] The following examples of the present application will further illustrate the nature of the present application. It should be understood that the following examples do not limit the present application, and the scope of the present application is determined by the appended claims.
[0456] Synthesis method
[0457] Unless otherwise indicated, abbreviations for chemical reagents and synthetic conditions have their general meanings known in the art and are as follows:
[0458] “LDA” means lithium diisopropylamide;
[0459] "EA" means ethyl acetate;
[0460] “PE” refers to petroleum ether;
[0461] “rt” and “rt” refer to room temperature;
[0462] "THF" means tetrahydrofuran;
[0463] "DEAD" means diethyl azodicarboxylate;
[0464] "TBAB" means tetrabutylammonium bromide
[0465] “DCM” means dichloromethane;
[0466] “HOBT” means hydroxybenzotriazole;
[0467] "LAH" means lithium aluminum hydride;
[0468] “TLC” means thin layer chromatography;
[0469] "Preparative TLC (prep-TLC)" means preparative thin layer chromatography;
[0470] “TMS-I” refers to trimethylsilyl iodide;
[0471] “Hex” refers to hexane;
[0472] “DMF” means dimethylformamide;
[0473] "h" means hour;
[0474] "EDCI" means 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;
[0475] "DMAP" means 4-dimethylaminopyridine;
[0476] “Prep-HPLC” means preparative high performance liquid chromatography;
[0477] “DHP” means dihydropyran;
[0478] "DPPF" means 1,1'-bis(diphenylphosphino)ferrocene; and
[0479] "DIEA" means diisopropylethylamine.
[0480] General Scheme 1: Preparation of Compound FC-1
[0481]
[0482] General procedure for the preparation of compound FI-2
[0483]
[0484] At -78 ° C, a solution of compound FI-1 (10 g, 68.04 mmol, 1.0 eq) in tetrahydrofuran (THF) (100 mL) was added to lithium diisopropylamide (LDA) (68 mL, 68.04 mmol, 1.0 eq). The mixture was stirred at -78 ° C for 1 hour. Compound 1a was then added and the mixture was stirred at -78 ° C for 3 hours. The reaction was quenched with a saturated aqueous solution of NH4Cl (100 mL) and extracted three times with ethyl acetate (EA) (50 mL×3). The organic layer was washed with brine and water, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (PE: EA, 10: 1) to obtain compound FI-2 (6.3 g, 53%).
[0485] General procedure for the preparation of compound FI-3
[0486]
[0487] To a mixture of compound FI-2 (5 g, 28.57 mmol, 1.0 eq) and compound 2a (5.4 g, 42.86 mmol, 1.5 eq) in THF (100 mL) at 0° C., NaH (1.37 g, 57.15 mmol, 2.0 eq) was added, and the mixture was stirred overnight at room temperature (rt) under a nitrogen atmosphere. The mixture was then concentrated to half the amount of solvent, 2.0 N HCl was then added to adjust pH=6, and filtered to give compound FI-3 (2.5 g, 40%), which was used in the next step without further purification.
[0488] Preparation of compound FC-1:
[0489]
[0490] At 0°C, compound 3-1 (700 mg, 5.68 mmol, 5.0 eq), PPh3 (600 mg, 2.28 mmol, 2.0 eq) and DEAD (396 mg, 2.28 mmol, 2.0 eq) were added to a solution of compound FI-3 (250 mg, 1.14 mmol, 1.0 eq) in THF (10 mL). The mixture was stirred at room temperature overnight. The mixture was then quenched with H2O (10 mL) and extracted with EA (10 mL*2). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel to give compound FI-4 (50 mg, 14%).
[0491] To a mixture of compound FI-4 (80 mg, 0.24 mmol, 1.0 eq) in MeOH (10 mL) was added KCN (32 mg, 0.24 mmol, 2.0 eq) and (NH4)2CO3 (92 mg, 0.48 mmol, 4.0 eq). The mixture was stirred overnight at 40 ° C in a nitrogen atmosphere. The mixture was then quenched with H2O (10 mL) and extracted with EA (10 mL*2). The organic layer was dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography to give compound FC-1 (5.6 mg, 12%).
[0492] Preparation of compounds FC-2, FC-3 and FC-4:
[0493] Compounds FC-2, FC-3 and FC-4 were synthesized using the same steps as FC-1, except that the raw material 3-a was replaced by compounds 3-2, 3-3 and 3-4 respectively:
[0494]
[0495] Preparation of compounds FC-5, FC-6 and FC-7:
[0496] Compounds FC-5, FC-6 and FC-7 were synthesized using the same steps as FC-1, except that the raw material 3-a was replaced by intermediates 3-5, 3-6 and 3-7:
[0497]
[0498] Preparation of intermediate 3-5:
[0499]
[0500] To a mixture of compound 3-3 (1 g, 8.13 mmol, 1.0 eq) in DCM (10 mL) was added m-CPBA (2.1 g, 12.195 mmol, 1.5 eq). The mixture was stirred at room temperature for 16 hours. The mixture was then filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound 3-5 (0.7 g, 62%).
[0501] Preparation of intermediates 3-6 and 3-7:
[0502] Intermediates 3-6 and 3-7 were synthesized using the same procedure as for the synthesis of Intermediate 3-5, except that the starting materials were replaced with starting materials 3-2 and 3-4, respectively.
[0503] General Scheme 2: Preparation of Compound FC-II
[0504]
[0505] General Scheme 3: Preparation of Intermediate 4a-1
[0506]
[0507] Synthesis of intermediate FI-5:
[0508] In a nitrogen atmosphere, a mixture of compound 2a (68 g, 538.9 mmol, 1.0 eq) in DMSO (500 mL) was stirred overnight at 80 ° C. The mixture was then diluted with H2O (1000 mL) and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to give compound FI-5 (67 g, 99%).
[0509] Synthesis of intermediate FI-6:
[0510] In a nitrogen atmosphere, at 60 ° C, a mixture of compound FI-5 (5 g, 19.97 mmol, 1.0 eq), compound 3b (7.39 g, 39.95 mmol, 2 eq) and K2CO3 (11.04 g, 79.89 mmol, 4.0 eq) in acetone (100 mL) was stirred for 4 h. The mixture was then diluted with H2O (1000 mL) and extracted with ethyl acetate. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (PE / EA, 10:1) to give compound FI-6 (8.7 g, 97%).
[0511] Synthesis of compound 4a-1:
[0512] To a mixture of compound FI-6 (10.7 g, 23.33 mmol, 1.0 eq) in THF (100 mL) was added PPh3 (6.11 g, 23.33 mmol, 1 eq), TBAB (15.04 g, 46.66 mmol, 2 eq) and 5% HCl (5 mL). The mixture was stirred for 12 h at rt under a nitrogen atmosphere. The mixture was then concentrated. The residue was purified by column chromatography on silica gel (PE / EA, 2:1) to give compound 4a-1 (6.6 g, 56%).
[0513] Preparation of compound FC-8:
[0514]
[0515] Under nitrogen atmosphere, at 0 ℃, to AlCl3 (1.34g, 10.2mmol, 3.0eq) in DCM (15mL) solution, AcCl (0.8g, 10.2mmol, 3.0eq) in DCM (5mL) solution was slowly added. The mixture was stirred at 0 ℃ for 30min. Then a solution of compound FI-1 (0.5g, 3.4mmol, 1.0eq) in DCM (5mL) was slowly added. The mixture was stirred at 0 ℃ for 20min. The mixture was then warmed to room temperature and stirred for 10min. The mixture was quenched with ice-cold water and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound FI-2a-1 (0.6g, 93%).
[0516] At 0 ° C, NaH (60 mg, 2.47 mmol, 2.0 eq) was added to a mixture of compound FI-2a-1 (0.2 g, 1.23 mmol, 1.0 eq) and compound 4a-1 (0.43 g, 1.85 mmol, 1.5 eq) in THF (10 mL). The mixture was allowed to warm to room temperature and stirred for 16 h under a nitrogen atmosphere. The mixture was then concentrated to half of the solvent, and 2N HCl was added to adjust pH = 6, filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel to give compound FI-7 (0.3 g, 83%).
[0517] To a mixture of compound FI-7 (0.3 g, 0.888 mmol, 1.0 eq) in MeOH (5 mL) was added KCN (115 mg, 1.775 mmol, 2.0 eq) and (NH4)2CO3 (341 mg, 3.550 mmol, 4.0 eq). The mixture was stirred at room temperature for 12 h. The mixture was then diluted with water and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC to give a colorless oily compound FC-8 (65 mg, 18%).
[0518] Alternative method for preparing intermediate FI-2a:
[0519]
[0520] Preparation of intermediate FI-2a-2:
[0521]
[0522] To a solution of compound FI-2 (5 g, 30.9 mmol, 1.0 eq) and isopentene (9 mL, 77.2 mmol, 2.5 eq) in tert-butanol (50 mL), NaClO2 (8.1 g, 89.6 mmol, 3.0 eq) and NaH2PO4·2H2O (10.3 g, 67.9 mmol, 2.2 eq) in H2O (70 mL) were slowly added. The mixture was stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure and diluted with H2O. 1 M HCl was then added to the mixture to adjust pH = 1, and filtered to give compound FI-2.1 (6.2 g, 100%).
[0523] To a mixture of compound FI-2.1 (5 g, 26.46 mmol, 1.0 eq) and TEA (8 g, 79.37 mmol, 3.0 eq) were added N, O-dimethylhydroxylamine (5.16 g, 52.91 mmol, 2.0 eq), HOBT (3.93 g, 29.1 mmol, 1.1 eq) and EDCI (6.06 g, 31.75 mmol, 1.2 eq). The mixture was stirred for 5 h. The mixture was then diluted with water and extracted with ethyl acetate. The organic phase was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound FI-2.2 (4.3 g, 67%).
[0524] To a mixture of compound FI-2.2 (1 g, 4.29 mmol, 1.0 eq) in anhydrous THF (10 mL) was added dropwise EtMgBr (1.0 mol / L in THF, 8.6 mL, 8.58 mmol, 2.0 eq) at 0°C in a nitrogen atmosphere. The mixture was stirred at 0°C for 1 h. The reaction was quenched with saturated aqueous NH4Cl solution and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine and water, dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel column chromatography to give compound FI-2a-2 (0.6 g, 69%).
[0525] Preparation of intermediates FI-2a-3, FI-2a-4 and FI-2a-5:
[0526]
[0527] The preparation processes of FI-2a-3, FI-2a-4 and FI-2a-5 were similar to the synthesis of FI-2a-2, except that i-BuMgBr, PrMgBr and i-PrMgBr were used to replace EtMgBr, respectively.
[0528] Preparation of compounds FC-9, FC-10, FC-11 and FC-12:
[0529]
[0530] At 0 ° C, NaH (79 mg, 1.98 mmol, 2.0 eq) was added to a mixture of compound FI-2a-2 (200 mg, 0.99 mmol, 1.0 eq) and compound 4a-1 (343 mg, 1.49 mmol, 1.5 eq) in THF (10 mL). The mixture was allowed to warm to room temperature and stirred for 16 h under a nitrogen atmosphere. The mixture was then concentrated to half of the solvent, and 2N HCl was then added to adjust pH = 6, filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography to give compound FI-7a (180 mg, 52%).
[0531] To a solution of compound FI-7a (180 mg, 0.511 mmol, 1.0 eq) in MeOH (5 mL) was added (NH4)2CO3 (196 mg, 2.05 mmol, 4.0 eq) and KCN (66 mg, 1.02 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. 3 M HCl was added to the reaction to adjust The mixture was stirred at room temperature for 1 h, then a saturated aqueous solution of NaHCO3 was added to adjust the pH to 6 to 7, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC to give FC-9 (48 mg, 22%) as a colorless oil.
[0532] The preparation process of FC-10, FC-11 and FC-12 is similar to the synthesis of FC-9, except that FI-2a-2 is replaced by FI-2a-3, FI-2a-4 and FI-2a-5 respectively.
[0533] General protocol for the preparation of compounds FC-13, FC-14, FC-15 and FC16:
[0534]
[0535] Compound FI-3 (895 mg, 3.876 mmol, 1.0 eq) and K2CO3 (2.14 g, 15.5 mmol, 4.0 eq) were added to a mixture of compound 3-8 (750 mg, 3.876 mmol, 1.0 eq) in DMF (15 mL) in sequence. The mixture was stirred at room temperature for 16 h under a nitrogen atmosphere. 3M HCl was then added to adjust pH = 6 to 7. The mixture was extracted with EA, the organic layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA, 1:1) to give compound FI-8 (610 mg, 36%).
[0536] To a solution of compound FI-8 (500 mg, 1.419 mmol, 1.0 eq) in MeOH (6 mL) was added (NH4)2CO3 (545 mg, 5.676 mmol, 4.0 eq) and KCN (185 mg, 2.838 mmol, 2.0 eq). The mixture was stirred at 45 ° C for 16 h. Then, 3M HCl was added to the reaction to adjust pH = 1 to 2, and stirred at room temperature for 1 h, then saturated NaHCO3 aqueous solution was added to adjust pH = 6 to 7, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC (prep-TLC) to give FC-13 (350 mg, 58%) as a white solid.
[0537] Compounds FC-14, FC15 and FC-16 were synthesized by the same steps as FC-13, except that intermediate 3-8 was replaced by intermediate 3-9, 3-10 or 3-11, respectively.
[0538] Preparation of intermediates 3-8, 3-9, 3-10 and 3-11:
[0539]
[0540] Preparation of intermediate 3-10
[0541] First, H2SO4 (2.5mL) was added to a mixture of 2-fluoroisonicotinic acid (5g, 35.5mmol, 1.0eq) in 2-methyl-1-propanol (75mL). The mixture was stirred at 115°C for 16h. TLC analysis of the reaction mixture showed complete conversion to the desired product. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Saturated NaHCO3 solution was added to the residue to adjust pH=8, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain compound 3I-1 (5g, 56%).
[0542] Under nitrogen atmosphere, LAH (1.96 g, 51.6 mmol, 2 eq) was quickly added to a mixture of compound 3I-1 (7 g, 25.8 mmol, 1.0 eq) in dry THF (100 mL) at 0 ° C. The mixture was stirred at 0 ° C for 1 h. TLC analysis of the reaction mixture showed complete conversion to the desired product. The reaction was quenched with Na2SO4·10H2O (7 g, 21.7 mmol, 0.8 eq) and the mixture was stirred for 0.5 h. The mixture was then filtered and the organic layer was concentrated in vacuo. The residue was purified by column chromatography on silica gel (PE / EA, 3:1) to give compound 3I-2 (3 g, 60%).
[0543] To a mixture of compound 3I-2 (4 g, 18.5 mmol, 1.0 eq) in DCM (100 mL) was added SOCl2 (2.7 mL, 37.1 mmol, 2.0 eq) dropwise under nitrogen atmosphere at 0° C. The mixture was stirred at 0° C. for 1 h. The reaction mixture was concentrated under reduced pressure to give compound 3-10 (4.2 g, 95%).
[0544] Intermediates 3-8, 3-9 and 3-11 were synthesized by the same procedure as Intermediate 3-10, except that 2-methyl-1-propanol was replaced with methanol (in the synthesis of Intermediate 3-8), ethanol (in the synthesis of Intermediate 3-9) and isopropanol (in the synthesis of Intermediate 3-11).
[0545] Preparation of compounds FC-17 and FC-18:
[0546]
[0547] To a mixture of compound SM-17 (1.7 g, 0.01 mol, 1.0 eq) in DCM was added (COCl) (2.5 g, 0.02 mol, 2.0 eq) dropwise at 0 °C. The mixture was stirred for 1 h while the solution became clear. The mixture was then concentrated under reduced pressure. To the DCM mixture of the residue was added a solution of NH in THF at -10 °C. The mixture was stirred for 0.5 h and then concentrated under reduced pressure to give compound FI-17a (1.3 g, 77%).
[0548] To a mixture of compound FI-17a (1.36 g, 5.92 mmol, 1.0 eq) in DMF (50 mL) were added compound 2a (1 g, 5.92 mmol, 1.0 eq) and K2CO3 (2.45 g, 17.76 mmol, 3.0 eq) in sequence. The mixture was stirred at room temperature for 16 h under a nitrogen atmosphere. TLC analysis of the reaction mixture showed complete conversion to the desired product. The mixture was then diluted with H2O (100 mL) and extracted with EA (3×100 mL). The combined organic layers were washed with a saturated aqueous solution of NH4Cl (3×100 mL), brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EA, 1:1) to give compound FI-17b (850 mg, 30%).
[0549] To a solution of compound FI-17b (850 mg, 2.41 mmol, 1.0 eq) in MeOH (10 mL) was added (NH4)2CO3 (934 mg, 9.64 mmol, 4.0 eq) and KCN (313 mg, 4.82 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. Then, 3M HCl was added to the reaction to adjust pH = 1 to 2, and stirred at room temperature for 1 h, then a saturated aqueous solution of NaHCO3 was added to adjust pH = 6 to 7, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by preparative TLC (prep-TLC) to give compound FC-17 (500 mg, 49%) as a white solid. Compound FC-18 was synthesized by the same steps as those for preparing FC-17, except that SM-18 was used instead of SM-17 as the starting material.
[0550] Preparation of compound FC-19:
[0551]
[0552] To a solution of compound FC-13 (500 mg, 1.21 mmol, 1.0 eq) in CHCl3 (30 mL) was added TMS-I (1.7 mL, 12.1 mmol, 10.0 eq). The mixture was stirred at 55 °C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by preparative TLC (prep-TLC) (EA: MeOH, 10: 1) to give compound FC-19 (100 mg, 21%) as a white solid.
[0553] Preparation of Intermediates 3-12, 3-13 and 3-14
[0554]
[0555] At room temperature, a solution of 3-(hydroxymethyl)phenol (0.5 g, 4.0 mmol), ethyl bromide (0.86 g, 8 mmol) and K2CO3 (2.2 g, 16 mmol) in ACN (20 mL) was stirred overnight. Water and EA were added to the reaction mixture and extracted twice with EA. The combined organic layers were dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography EA / Hex (EA / Hex=1:4) to give an oily intermediate 3-12a (0.48 g, 79%).
[0556] PBr3 (0.15mL, 1.5mmol, 33% acetic acid solution) is added to a solution of intermediate 3-12a (0.18g, 1.1mmol) in DCM (20mL). The reaction mixture is stirred at room temperature for 1 hour, DCM and water are added, and extracted twice with DCM. The combined organic layer is dried with MgSO4 and evaporated under high vacuum. The residue is purified by flash chromatography EA / Hex (EA / Hex=1:4) to obtain intermediate 3-12 (0.16g, 63%) as a white solid. Intermediates 3-13 and 3-14 are synthesized by the same steps as those for preparing intermediate 3-12, except that bromoethane is replaced with 2-bromopropane or 1-bromopropane as a starting material.
[0557] Preparation of intermediates 3-15, 3-16 and 3-17:
[0558]
[0559] HBr (33% acetic acid solution, 0.18 mL, 1 mmol) was added dropwise to a solution of 1,4-benzenedimethanol (0.14 g, 1 mmol) in DCM (5 mL). The reaction mixture was stirred at room temperature for 1 hour. The spots of the starting material (SM) were determined to disappear by TLC. EA and water were added to the reaction mixture and extracted twice with EA. The combined organic layers were dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography EA / Hex (EA / Hex=1:10 to 1:4) to give intermediate 3-15 (0.4 g, 52%) as a white solid. Intermediates 3-16 and 3-17 were synthesized by the same steps, except that intermediate 3-16a or 3-17a was used instead of intermediate 3-15a as a starting material.
[0560] General protocol for the preparation of compounds FC-20 to FC-25 :
[0561]
[0562] A solution of 1-bromomethyl-3-ethoxy-benzene 3-12 (0.42 g, 1.96.mmol), FI-3 (0.43 g, 1.96.mmol) and K2CO3 (0.83 g) in ACN was stirred at room temperature overnight. The reaction was checked by TLC (EA / Hex=1 / 3) and the disappearance of the benzyl bromide spot was confirmed. EA and water were added to the reaction mixture and extracted twice with EA. The combined organic layer was dried over MgSO4 and purified on a silica gel column to give intermediate FI-20 (0.52 g, 60%). Intermediates FI-21, FI-22, FI-23, FI-24 and FI-25 were synthesized using the same steps, except that the starting material 3-12 was replaced with the starting material 3-13, 3-14, 3-15, 3-16 or 3-17, respectively.
[0563] To a solution of FI-20 (0.52 g, 1.41 mmol) in EtOH / H2O (10 mL / 5 mL) was added (NH4)2CO3 (2.01 g, 21.0 mmol) and KCN (0.16 g, 2.31 mmol). The reaction mixture was stirred at room temperature overnight. The solution was evaporated to remove most of the solvent. Water was added to the mixture, which was then extracted twice with EA. The organic layers were combined, dried over MgSO4 and evaporated. The residue was purified by flash chromatography EA / hexane (EA / hexane=1:1) to give FC-20 (0.22 g, 38%) as a light yellow solid. Compounds FC-21, FC-22, FC-23, FC-24 and FC-25 were synthesized by the same steps, except that the intermediate FI-20 was replaced by the intermediate FI-21, FI-22, FI-23, FI-24 or FI-25, respectively.
[0564] Preparation of compound FC-26:
[0565]
[0566] In an ice bath, PBr3 (1.5 mL, 15.8 mmol) was added dropwise to a solution of 3-hydroxybenzyl alcohol (1.5 g, 12.1 mmol) in DCM (45 mL). The mixture was stirred at room temperature for 1 hour. The reaction was monitored to completion by TLC (EA / Hex=1 / 10). DCM and water were then added to the reaction mixture and extracted twice with DCM. The combined organic layers were filtered with silica gel and MgSO4 and evaporated under high vacuum. The white solid intermediate 3-18 was used in the next step without further purification (1.27 g, 57%).
[0567] At room temperature, to the DCM (30mL) solution of intermediate 3-18 (1.27g, 6.79mmol) and imidazole (0.92g, 13.58mmol) was added dropwise a DCM solution of TBSC1 (1.53g, 10.2mmol, 5mL). The reaction mixture was stirred overnight at room temperature. DCM and water were added to the reaction mixture and extracted twice with DCM. The combined organic layer was dried with MgSO4, filtered through silica gel, and evaporated under high vacuum. The oily compound 3-18a can be used in the next step (1.7g, 84%) without further purification.
[0568] A solution of compound 3-18a (1.7 g, 5.8 mmol), compound FI-3 (1.28 mg, 5.8 mmol) and K2CO3 (3.5 g, 22 mmol) in ACN (10 mL) was stirred at room temperature overnight. Water and EA were added to the reaction mixture, and extracted twice with EA. The combined organic layer was dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography with EA / Hex (EA / Hex=1:4) to give compound FI-026a (1.2 g, 47%).
[0569] To a solution of compound FI-026a (1.03 g) in DCM (25 mL) was added TFA (1 mL) at room temperature. The reaction mixture was stirred overnight, and then the solvent and TFA were removed. NaHCO3 and MeOH were added to the brown oil. The solvent was then removed again. The residue was purified by flash chromatography with EA / Hex (EA / Hex=1:4) to give FI-026b (0.14 g) as a white solid.
[0570] To a solution of compound FI-026b (0.2 g, 0.61 mmol) in EtOH / H2O (5 mL / 2.5 mL) was added (NH4)2CO3 (0.35 g, 3.66 mmol) and KCN (47 mg, 0.74 mmol). The reaction mixture was stirred at room temperature overnight. The solution was evaporated to remove most of the solvent. Water and EA were added to the mixture, and then extracted twice with EA. The organic layers were combined, dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography using DCM / MeOH (DCM / MeOH=20:1) to give compound FC-26 (0.11 g, 45%) as a white solid.
[0571] Preparation of compound FC-27:
[0572]
[0573] A mixture of propargyl alcohol (0.6 ml, 103.82 mmol), DHP (1.2 ml, 13.5 mmol) and PPTS (21 mg, 0.1 mmol, 1 mol%) was stirred for 1 h at 0° C. The reaction mixture was directly purified by silica gel column chromatography (Hex: Et2O, 30:1) to give FI-1b.1 (11 g, 78%).
[0574] To a stirred solution of THP protected propargyl alcohol FI-1b.1 (0.52 g, 3 mmol) in THF (15 mL) at -78 °C, n-butyl lithium solution (1.5 mL, 3.6 mmol, 2.5 M in hexanes) was added. The reaction was stirred for 30 min, then acetaldehyde (0.18 mL, 3.3 mmol) was added. The mixture was stirred for 2 h, then stirred at 0 °C for 30 min. The mixture was washed with ether / NH4Cl (饱和) The reaction mixture was extracted and concentrated to give FI-1b.2 (0.12 g, 22%) as an oil.
[0575] To a stirred solution of FI-1b.2 (0.12 g, 0.65 mmol) in DCM (5 mL) was added MnO2 (67 mg, 0.78 mmol) at 0°C overnight. TLC evaluation of the reaction indicated that starting material was still present. Additional MnO2 (0.15 g) was then added and the solution was stirred for an additional 16 hours. The reaction mixture was filtered through MgSO4 and silica gel. The residue was purified by flash chromatography using EA / Hex (EA / Hex=1:4) to give FI-1b.3 (0.1 g, 90%) as an oil.
[0576] To a stirred solution of FI-1b.3 (1.8 g, 10 mmol) in MeOH (50 mL) was added PPTS (0.5 g). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with H2O and EA. The aqueous phase was extracted with EA, the combined organic portions were washed with brine, and the solvent was removed. The residue was purified by flash chromatography with EA / Hex (EA / Hex=3:1) to give FI-1b.4 (1 g, ~100%) as a yellow liquid.
[0577] To a stirred solution of FI-1b.4 (0.1 g, 1 mmol) in toluene (5 mL) was added HBr (1 mL, 2 M HBr) at room temperature. (水溶液) ). The mixture was diluted with toluene and water. The aqueous phase was extracted with toluene. The combined organic portions were washed with brine. The crude NMR of the toluene solution was checked and indicated the presence of the desired product FI-1b (0.15 g). The toluene solution of FI-1b was used in the next step without further purification.
[0578] POCl3 (0.1 mL, 1.1 mmol) was added dropwise to DMF (1 mL) at room temperature. A solution of FI-1b (0.15 g) in toluene (5 mL) was added to the DMF / POCl3 solution under stirring. After 2 hours, the reaction mixture was treated with NaHCO 3(饱和水溶液) Neutralize and stir for 30min. The aqueous phase is extracted with EA, the organic phase liquid is combined, washed with brine, dried over MgSO44 and the solvent is removed. The crude NMR was checked, indicating the presence of the desired product FI-2b (0.18g). FI-2b can be used for the next step without further purification. To a THF (5mL) solution of FI-2b (0.18g) was added NaOH (60mg) and 4-mercaptophenol (0.13g, 1mmol), and the reaction mixture was stirred overnight. The reaction mixture was extracted with EA and water, washed with brine, dried over MgSO4 and the solvent was removed. The residue was purified by flash chromatography with EA / Hex (EA / Hex=1 / 4) to obtain the desired product FI-3b (0.14g, 60%) as an intermediate for the synthesis of FC-27 and FC-28.
[0579] A solution of FI-3b (0.3 g, 1.28 mmol), 3-methylbenzyl bromide (0.3 mg, 1.92 mmol) and K2CO3 (0.71 g, 5.12 mmol) in ACN (6 mL) was stirred at room temperature overnight. Water and EA were added to the reaction mixture and extracted twice with EA. The combined organic layers were dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography with EA / Hex (EA / Hex=1:4) to give FI-027 (0.34 g, 79%) as a yellow oil.
[0580] To a solution of FI-027 (0.34 g, 1.0 mmol) in EtOH / H2O (5 mL / 2.5 mL) was added (NH4)2CO3 (0.58 g, 6 mmol) and KCN (78 mg, 1.2 mmol). The reaction mixture was stirred at room temperature overnight. The solution was evaporated to remove most of the solvent. Water and EA were added to the mixture, which was then extracted twice with EA. The organic layers were combined, dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography using DCM / MeOH (DCM / MeOH=50:1-30:1) to give FC-27 (105 mg, 25%) as a yellow solid.
[0581] Preparation of compound FC-28:
[0582]
[0583] A solution of FI-3b (0.3 g, 1.28 mmol), 3-15 (0.3 mg, 1.92 mmol), K2CO3 (0.71 g, 5.12 mmol) in ACN (6 mL) was stirred at room temperature overnight. Water and EA were added to the reaction mixture, and extracted twice with EA. The combined organic layers were dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography with EA / Hex (EA / Hex=1:4) to give FI-028 (0.34 g, 79%) as a yellow oil.
[0584] To a solution of FI-028 (0.34 g, 1.0 mmol) in EtOH / H2O (5 mL / 2.5 mL) was added (NH4)2CO3 (0.58 g, 6 mmol) and KCN (78 mg, 1.2 mmol). The reaction mixture was stirred at room temperature overnight. The solution was evaporated to remove most of the solvent. Water and EA were added to the mixture, which was then extracted twice with EA. The organic layers were combined, dried over MgSO4 and evaporated under high vacuum. The residue was purified by flash chromatography using DCM / MeOH (DCM / MeOH=50:1-30:1) to give FC-28 (105 mg, 25%) as a yellow solid.
[0585] Preparation of compound FC-29:
[0586]
[0587] To a solution of compound 4-pyridinemethanol (5 g, 45.82 mmol, 1.0 eq) and imidazole (7.97 g, 137.45 mmol, 3.0 eq) in DCM (100 mL) was added TBSCl (13.8 g, 91.64 mmol, 2.0 eq) at 0 ° C. The mixture was stirred at room temperature for 2 h. The mixture was then quenched with saturated NH4Cl solution (100 mL). The mixture was extracted with ethyl acetate (50 mL×3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound FI-29a (7.2 g, 70%).
[0588] At room temperature, m-CPBA (11.58 g, 67.14 mmol, 1.5 eq) was added to a solution of compound FI-29a (10 g, 44.76 mmol, 1.0 eq) in DCM (150 mL). The mixture was stirred at room temperature for 16 h. TLC analysis of the reaction mixture showed complete conversion to the desired product. The mixture was then quenched with saturated aqueous sodium sulfite solution. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound FI-29b (8.1 g, 75%).
[0589] To a mixture of compound FI-29b (10.3 g, 43.4 mmol, 1.0 eq) in TEA (40 mL) was added trimethylsilyl cyanide (13 g, 130.4 mmol, 3 eq). The mixture was heated at 90 ° C for 3 hours under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-29c (5.1 g, 47%).
[0590] To a solution of FI-29c (5.1 g, 20.53 mmol, 1.0 eq) in ethanol / H2O (100 / 17 mL) was added NaOH (6.9 g, 172.5 mmol, 8.4 eq). The mixture was stirred at 90°C for 2 h. The mixture was then cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate. The aqueous layer was acidified to pH = 4-5 and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-29d (3.2 g, 99%).
[0591] To a solution of FI-29d (2.2 g, 14.36 mmol, 1.0 eq) in DMF (100 mL) was added NH4Cl (1.54 g, 28.73 mmol, 2.0 eq), HATU (5.46 g, 14.36 mmol, 1.0 eq) and DIEA (5.57 g, 43.08 mmol, 3.0 eq) in sequence. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (200 mL), washed with brine, water, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-29e (0.6 g, 27%).
[0592] To a mixture of FI-29e (0.53 g, 3.48 mmol, 1.0 eq) in DCM (50 mL) was added SOCl2 (0.83 g, 6.96 mmol, 2.0 eq) dropwise under nitrogen at 0°C. The mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with DCM (50 mL) and washed with a saturated aqueous solution of NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to give FI-29f (0.47 g, 79%).
[0593] FI-3 (607 mg, 2.75 mmol, 1.0 eq) and K2CO3 (759 mg, 5.5 mmol, 2 eq) were added to a solution of FI-29f (470 mg, 2.75 mmol, 1.0 eq) in DMF (20 mL). The mixture was stirred at room temperature for 4 h. The mixture was then diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-29g (210 mg, 22%).
[0594] To a solution of FI-29g (250 mg, 0.71 mmol, 1.0 eq) in MeOH (7 mL) was added (NH4)2CO3 (270 mg, 2.82 mmol, 4.0 eq) and KCN (91 mg, 1.41 mmol, 2.0 eq). The mixture was stirred at 45°C for 16 h. 3M HCl was added to the reactant to adjust pH = 1-2, and stirred at room temperature for 1 h, then a saturated aqueous solution of NaHCO3 was added to adjust pH = 7-8, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FC-29 (75 mg, 25%) as a white solid.
[0595] Preparation of compound FC-30:
[0596]
[0597] In a nitrogen atmosphere, at -78 ° C, TEA (20.63 g, 189.34 mmol, 3 eq), (CF3SO2)2O (19.59 g, 69.42 mmol, 1.1 eq) were added to a solution of compound FI-3 (13.9 g, 63.11 mmol, 1.0 eq) in DCM (500 mL). The mixture was stirred at -78 ° C for 2 h under a nitrogen atmosphere. The mixture was then warmed to 0 ° C and quenched with a saturated Na2CO3 (200 mL) solution. The organic phase was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give compound FI-30a (9.7 g, 44%).
[0598] Under nitrogen atmosphere, 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborane (1.2 g, 7.83 mmol, 1.1 eq), Pd(dppf)2Cl2 (0.52 g, 0.71 mmol, 0.1 eq) and CsF (2.8 g, 15.45 mmol, 2 eq) were added to a solution of FI-30a (2.5 g, 7.12 mmol, 1.0 eq) in dioxane / H2O (5 / 1, 60 mL) in sequence. The mixture was stirred at 85 °C for 16 h. The reaction was then cooled to room temperature and quenched with H2O (50 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-30b (1.3 g, 79%).
[0599] To a solution of FI-30b (1.3 g, 5.65 mmol, 1.0 eq) in DCM (50 mL) was added 2-methyl-4-vinylpyridine (0.74 g, 6.21 mmol, 1.1 eq) and Hoveyda-Grubbs II reagent (354 g, 0.57 mmol, 0.1 eq). The mixture was stirred at 50 ° C for 14 h under nitrogen atmosphere. The mixture was then diluted with DCM (100 mL) and washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-30c (0.3 g, 16%).
[0600] Pd / C was added to the methanol solution of FI-30c. The mixture was stirred at room temperature for 16 h under hydrogen atmosphere (20 psi). The mixture was filtered and the filtrate was concentrated and purified to give FI-30d.
[0601] (NH4)2CO3 and KCN were added to the FI-30d solution. The mixture was stirred at 45°C for about 16 h. Then, 3M HCl was added at room temperature to adjust the pH to 1-2 for 1 h, and then a saturated aqueous solution of NaHCO3 was added to adjust the pH to 7-8. The mixture was extracted and the residue was purified by silica gel chromatography to obtain FC-30.
[0602] Preparation of compound FC-31:
[0603]
[0604] The starting material methyl 2-methylisonicotinate (20 g, 132.31 mmol, 1.0 eq) was dissolved in NH3 / MeOH (100 mL, 500 mmol, 3.78 eq, 5 M) and stirred at room temperature under nitrogen atmosphere for 6 h. The mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-31a (10.2 g, 56%).
[0605] To a mixture of FI-31a (7.65 g, 56.18 mmol, 1.0 eq) in THF (250 mL) was added LiAlH4 (6.4 g, 168.56 mmol, 3 eq) at 0°C in a nitrogen atmosphere. The mixture was stirred at 70°C for 6 h. The mixture was then cooled to 0°C and quenched with saturated Na2SO4 solution (100 mL). The mixture was filtered and the filtrate was extracted with DCM (3×30 mL). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-31b (0.9 g, 13%).
[0606] In a nitrogen atmosphere, xantphose (65 mg, 0.11 mmol, 0.1 eq), Pd2(dba)3 (103 mg, 0.11 mmol, 0.1 eq) and Cs2CO3 (1.1 g, 3.4 mmol, 3 eq) were added to a solution of FI-30a (400 mg, 1.13 mmol, 1.0 eq) and FI-31b (183 mg, 1.13 mmol, 1.0 eq) in dioxane (20 mL) in sequence. The mixture was stirred at 110 ° C for 16 h under a nitrogen atmosphere. The mixture was then quenched with H2O (50 mL) and extracted with ethyl acetate (100 mL×3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-31c (80 mg, 22%).
[0607] To a solution of FI-31c (180 mg, 0.55 mmol, 1.0 eq) in MeOH (5 mL) was added (NH4)2CO3 (213 mg, 2.22 mmol, 4.0 eq) and KCN (72 mg, 1.11 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. 3 M HCl was added to the reaction to adjust The mixture was stirred at room temperature for 1 h, and then a saturated aqueous solution of NaHCO3 was added to adjust the The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FC-31 (33 mg, 15%) as a yellow solid.
[0608] Preparation of compound FC-32:
[0609]
[0610] To a mixture of FI-2a2 (600 mg, 2.97 mmol, 1.0 eq) and 4-mercaptophenol (450 mg, 2.97 mmol, 1.0 eq) in THF (10 mL) was added NaH (143 mg, 3.56 mmol, 1.2 eq) at 0 ° C. The mixture was allowed to warm to room temperature and stirred for 16 h under a nitrogen atmosphere. The mixture was then concentrated to half the amount of solvent, 2N HCl was then added to adjust pH = 6, filtered and the filtrate was concentrated. The residue was purified by silica gel column chromatography to give compound FI-32a (750 mg, 99%).
[0611] To a mixture of FI-32a (680 mg, 2.62 mmol, 1.0 eq) and 4-(chloromethyl)-2-methylpyridine (557 mg, 3.94 mmol, 1.5 eq) in DMF (20 mL) was added KCO (1.08 g, 7.87 mmol, 3 eq). The mixture was stirred at 70 ° C for 4 h under a nitrogen atmosphere. The mixture was then quenched with H O (60 mL) and extracted with ethyl acetate (40 mL×3). The combined organic phases were washed with brine, dried over anhydrous Na SO, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-32b (740 mg, 80%).
[0612] To a solution of FI-32b (800 mg, 2.26 mmol, 1.0 eq) in MeOH (20 mL) was added (NH4)2CO3 (870 mg, 9.06 mmol, 4.0 eq) and KCN (294 mg, 4.5 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. 3M HCl was added to the reactant to adjust pH = 1-2, and stirred at room temperature for 1 h, then saturated NaHCO3 aqueous solution was added to adjust pH = 7-8, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FC-32 (720 mg, 75%) as a white solid.
[0613] Preparation of compound FC-33:
[0614]
[0615] To a solution of FI-30a (7.0 g, 19.87 mmol, 1.0 eq) in toluene (100 mL) were added ethane-1,2-diol (24.6 g, 397.3 mmol, 20 eq) and TsOH (0.16 g, 0.99 mmol, 0.05 eq) in sequence. The mixture was heated to reflux for 12 h under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give FI-33a (3.78 g, 48%).
[0616] In a nitrogen atmosphere, xantphose (561 mg, 0.95 mmol, 0.1 eq), Pd2(dba)3 (889 mg, 0.95 mmol, 0.1 eq) and Cs2CO3 (9.31 g, 28.59 mmol, 3 eq) were added to a solution of FI-33a (3.78 g, 9.53 mmol, 1.0 eq) and FI-31b (1.16 g, 9.53 mmol, 1.0 eq) in dioxane (100 mL) in sequence. The mixture was stirred at 110 ° C for 16 h under a nitrogen atmosphere. The mixture was then quenched with H2O (50 mL) and extracted with ethyl acetate (100 mL*3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-33b (800 mg, 22%).
[0617] To a solution of FI-33b (800 mg, 2.17 mmol, 1.0 eq) in formic acid (10 mL, 40%) was added formaldehyde (13 mg, 4.34 mmol, 2.0 eq). The mixture was stirred at 100 ° C for 16 h under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure, diluted with an aqueous NaHCO3 solution, and extracted with ethyl acetate (100 mL*3). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-33c (180 mg, 24%).
[0618] To a solution of FI-31c (300 mg, 0.89 mmol, 1.0 eq) in MeOH (5 mL) was added (NH4)2CO3 (340 mg, 3.54 mmol, 4.0 eq) and KCN (115 mg, 1.77 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. 3 M HCl was added to the reaction to adjust The mixture was stirred at room temperature for 1 h, and then a saturated aqueous solution of NaHCO3 was added to adjust the The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FC-33 (38 mg, 10%) as a yellow solid.
[0619] Preparation of compound FC-34:
[0620]
[0621] At 0 ° C, NaH (1.14 g, 28.57 mmol, 1.0 eq) and methyl 4-mercaptobenzoate (4.8 g, 28.57 mmol, 1.0 eq) were added to a mixture of THF (100 mL). The mixture was allowed to warm to room temperature and stirred for 4 h under a nitrogen atmosphere. The mixture was then quenched with ice water (100 mL), 2N HCl was added to adjust pH = 7, and extracted with EA (3 × 50 mL). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-34a (2.7 g, 36%).
[0622] To a solution of FI-34a (4.8 g, 18.3 mmol, 1.0 eq) in toluene (100 mL) was added ethane-1,2-diol (22.7 g, 36.6 mmol, 20 eq) and TsOH (0.16 g, 0.9 mmol, 0.05 eq) in sequence. The mixture was heated to reflux for 12 h under a nitrogen atmosphere. The mixture was then concentrated under reduced pressure. The residue was purified by silica gel column chromatography to give FI-34b (2.4 g, 36%).
[0623] To a solution of FI-34b (2.4 g, 7.83 mmol, 1.0 eq) in THF (80 mL) was added LiAlH4 (0.89 g, 23.5 mmol, 3 eq) at 0°C in a nitrogen atmosphere. The mixture was stirred at room temperature for 2 h. The mixture was then cooled to 0°C and quenched with 1N HCl (30 mL). The mixture was extracted with DCM (3×50 mL). The combined organic phases were washed with a saturated aqueous solution of NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-34c (2.0 g, 22%).
[0624] To a solution of FI-34c (1.0 g, 3.59 mmol, 1.0 eq) in DCM (20 mL) was added SOCl2 (0.85 g, 7.18 mmol, 2 eq) at 0°C under nitrogen atmosphere. The mixture was stirred at room temperature for 2 h. The mixture was then concentrated under reduced pressure to give FI-34d (1.01 g, 99%), which was used directly in the next step.
[0625] 4-Amino-2-methylpyridine (0.26 g, 2.36 mmol, 1.0 eq) and K2CO3 (0.65 g, 4.7 mmol, 2 eq) were added to a solution of FI-34d (0.7 g, 2.36 mmol, 1.0 eq) in DMF (20 mL). The mixture was stirred at 45 ° C for 12 h. The mixture was then diluted with water (50 mL) and extracted with ethyl acetate (30 mL×3). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-34e (0.5 g, 57%).
[0626] A mixture of FI-34e (0.8 g, 2.17 mmol, 1.0 eq) in HCl / THF (3.0 M, 3 mL / 3 mL) was stirred at 80 ° C for 16 h. The reaction mixture was concentrated under reduced pressure. Saturated NaHCO3 solution was added to the residue to adjust pH = 8, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FI-34f (0.5 g, 70%).
[0627] To a solution of FI-34f (0.5 g, 1.54 mmol, 1.0 eq) in MeOH (5 mL) was added (NH4)2CO3 (0.59 g, 6.16 mmol, 4.0 eq) and KCN (0.2 g, 3.08 mmol, 2.0 eq). The mixture was stirred at 45 °C for 16 h. 3 M HCl was added to the reaction to adjust The mixture was stirred at room temperature for 1 h, and then a saturated aqueous solution of NaHCO3 was added to adjust the The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel chromatography to give FC-34 (41 mg, 6%) as a yellow solid.
[0628] Biological Testing
[0629] Example 1: MMP inhibition assay
[0630] The inhibitory effect of the compound on the rate of cleavage of the fluorescent MMP substrate (Enzo, BML-P128) by the recombinant human MMP-12 catalytic domain (Enzo, BML-SE138) was performed by methods known in the art. Briefly, all reagents were added to each well of a 96-well black opaque plate by pipetting, and the final reaction contained 4 nM recombinant human MMP-12 catalytic domain, 4 μM fluorescent MMP substrate and various concentrations (0.15 nM to 10,000 nM) of the test compound in HEPES buffer (pH 7.5) containing 10 mM CaCl2, 0.01% 35 (polyoxyethylene (23) lauryl ether) and 0.1 mg / ml BSA.
[0631] The enzyme and compound were pre-incubated on a shaker and mixed in the wells. After one hour of mixing, the fluorescent substrate was added to each well. The reaction without enzyme on the plate was used as a blank control. The plate was then sent to a plate reader to measure the fluorescence intensity at an excitation / emission wavelength of 340nm / 440nm every 10 minutes for at least 1 hour at 37°C. The IC of each compound in MMP-12 inhibition was determined by using the readings obtained at the 30-minute time point. 50 Table 1 lists the results for each compound tested.
[0632] Example 2: Selectivity Assay
[0633] MMP selectivity assays were performed using other recombinant human MMPs including MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13, and MMP-14. IC values of compounds against other recombinant human MMPs 50 The assay was performed as described above in Example 1 and shown in Table 2.
[0634] Table 2: MMP-12 selection profile of compounds according to examples of the present application
[0635]
[0636] A = less than 10 nM, B = 10 nM to 100 nM, C = 100 nM to 1000 nM, D = 1000 nM to 10000 nM, E = greater than 100001 nM
[0637] The results in Table 2 above indicate that the compounds according to the embodiments of the present application have high selectivity for MMP-12 compared to other MMPs including MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-13 and MMP-14.
[0638] Example 3: Study on the efficacy of MMP-12 inhibitors on idiopathic pulmonary fibrosis (IPF) in the bleomycin-induced unilateral pulmonary fibrosis model of SD rats
[0639] The aim of this study was to evaluate the therapeutic effect of FC-4 on the bleomycin (BLM)-induced unilateral pulmonary fibrosis model in Sprague-Dawley (SD) rats. Male SD rats (n=50) were randomly divided into the following groups: sham group (n=10), model group (n=10), group administered with FC-4 at a dose of 10 mg / kg / day (n=10), group administered with FC-4 at a dose of 30 mg / kg / day (n=10), and group administered with FC-4 at a dose of 100 mg / kg / day (n=10). All tested drugs were orally administered for 14 days starting from the 8th day of modeling. Saline solution was administered once a day in the sham and model groups, and FC-4 was administered twice a day in the drug-treated groups. Rats were anesthetized and the trachea was exposed. In the sham group, saline was injected by direct intratracheal injection, and animals in other groups received an injection of BLM at a dose of 3 mg / kg in a volume of 1.0 ml / kg. All animals were tested for noninvasive lung function using the EMMS whole body plethysmography system at pre-modeling and on modeling days 3, 7, 11, 14, 18, and 21. On the second day after the last administration, the left lungs of all animals were perfused with 10% formalin and subjected to pathological analysis.
[0640] After modeling, all animals showed minimal changes in lung function in tidal volume (TV), respiratory rate, minute inspiratory volume (MV), and Penh index. At each time point tested, FC-4 treatment did not significantly affect lung function, and there was no significant difference compared with vehicle animals. Histological examination showed that the lung fibrosis in the model group showed hyperplasia of bronchial and alveolar duct epithelial cells, different amounts of mucus in the bronchial cavity, and inflammatory cell infiltration, especially in the adventitia area. Due to the shedding and regeneration of alveolar epithelial cells, inflammatory cell infiltration and fibrosis of the alveolar wall, alveolar damage in the fibrotic core was caused, and inflammatory cell infiltration of the alveolar cavity accompanied by fibrotic masses was observed. Compared with the model group, animals treated with FC-4 at a dose of 10 mg / kg / day showed a significant therapeutic effect on lung fibrosis. Increasing the dose of FC-4 to 30 mg / kg / day and 100 mg / kg / day also showed a significant therapeutic effect, but no obvious dose-dependent effect was observed. Fibrosis Ashcraft score data showed that FC-4 significantly reduced fibrosis scores. Biomarker analysis using immunohistochemistry (IHC) showed that FC-4 treatment had similar reductions in collagen I and collagen IV deposition in the fibrotic core; the expression of MMP-12, TGF-β1, and elastin in the fibrotic core was also significantly reduced.
[0641] In summary, a BLM-induced unilateral pulmonary fibrosis model was successfully established. Oral administration of FC-4 for 2 weeks starting from day 8 of the pulmonary fibrosis model provided significant therapeutic effects at doses of 10 mg / kg / day, 30 mg / kg / day, or 100 mg / kg / day. Treatment with FC-4 also showed significant therapeutic effects on pulmonary fibrosis when all dose groups were compared with the model group. Analysis of fibrosis-related biomarkers showed that FC-4 treatment reduced the expression of related biomarkers and collagen deposition in the fibrotic core, indicating the therapeutic mechanism of FC-4 for IPF.
[0642] Detailed experimental methods
[0643] Animals: Species and quality grade: SD rats, SPF grade. Gender and number: male, 93. Purchase weight range: 260-280 g. Company certificate number: SCXX (Jing) 2012-001, Beijing Vital River Laboratory Animal Technology Co., Ltd. Animal husbandry: Rats were kept in the animal facility of Nanjing BioSciKin Co. Ltd. in accordance with international standard temperature, humidity and light control systems. The animal use protocol has been reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of KCI Biotech Inc. All experimental procedures were performed in accordance with the institutional guidelines of KCI Biotech Inc.
[0644] Model establishment: This study was conducted in strict accordance with the guidelines of the SOP institution for the care and use of experimental animals. Rats were anesthetized with an intraperitoneal injection of sodium pentobarbital at a dose of 50 mg / kg. The skin of the rat neck was then disinfected and layered. The trachea was carefully exposed. Bleomycin (BLM) was injected directly into the left main bronchus through the cannula at a dose of 3 mg / kg body weight in a volume of 1.0 ml / kg. After the layered trachea and skin were closed, the animals were moved to a heating pad at 37°C, waited for awakening after anesthesia, and then returned to the cage with free access to water and food.
[0645] Experimental grouping: Rats were divided into 5 groups: sham operation group (Group 1, n = 10), model group (Group 2, n = 10), FC-4-low dose (Group 3, 10 mg / kg / day, n = 10), FC-4-medium dose (Group 4, 30 mg / kg / day, n = 10), FC-4-high dose (Group 5, 100 mg / kg / day, n = 10) (Table 1). Administration: The test article FC-4 was designed to be administered orally by gastric perfusion. Starting from the 8th day of modeling, FC-4 was administered twice a day for a total of 14 days (Table 3.1).
[0646] Endpoints: a) Non-invasive pulmonary function test: At multiple time points during the study (including before IPF modeling, IPF day 3, IPF day 7 before dosing, IPF day 11, IPF day 14, IPF day 18, and IPF day 21 before killing the animals), all animals were subjected to non-invasive pulmonary function tests using the EMMS whole body plethysmography (WBP) system, focusing on the following parameters: tidal volume (TV), respiratory rate, minute inspiratory volume (MV), and Penh. index. b) Collection of left lung for pathological analysis: After the last lung function test, all animals were euthanized according to KCI's standard SOP. After confirming the death of the animal, each animal received a systemic perfusion of 10% formaldehyde solution, and then the left lung was collected and perfused again with an equal volume of 10% formaldehyde solution (3 ml per lung). Lung pathology was performed after lung fixation. c) Pathological analysis of the left lung: According to the KCI pathology SOP, the entire left lung was dehydrated and wax-embedded, and then sectioned at a thickness of 3 μm. Hematoxylin and eosin (H&E) and Masson's trichrome staining were performed according to the KCI Pathology Standard SOP, and the entire slide was scanned using the Hamamatsu NanoZoomer Digital Pathology S210 slide scanner. H&E-stained slides were scored for bronchiolar and pulmonary arteriolar damage and inflammatory cell infiltration in the fibrotic core and fibrotic plate areas according to the criteria listed in Tables 3.2 and 3.3 (see also Figure 1A ). According to the standards and Figure 1B , the left lung injury area and pathological fibrosis score induced by BLM were evaluated with slides stained with Masson's trichrome. In addition, five animals were randomly selected from each group (three animals were selected from the sham group) for biomarker analysis using IHC methods, such as collagen I (Abcam, Cat#ab34710), collagen IV (Abcam, Cat#ab6586), MMP-12 (LSBio, Cat#LS-C497709), TGF-β1 (Invitrigen, Cat#MA5-16949) and elastin (Abcam, Cat#GR134273-29). IHC staining was processed according to KCI's IHC standard procedures. The stained slides were then scanned by Hamamatsu NanoZoomer Digital Pathology S210 slide scanner and analyzed using the software to obtain positive staining area / analysis area (%). d) Statistical analysis: Statistical analysis was performed using Graphpad Prism 5.0 software. The results described are expressed as mean ± SEM or mean ± SD. Statistical comparisons were performed using t-test, one-way ANOVA, or two-way ANOVA test. p < 0.05 was considered statistically significant.
[0647] Table 3.1. Animal experimental groups
[0648]
[0649] 1 CPD dose = compound dose
[0650] Table 3.2. Grading criteria for bronchiolar damage and inflammatory cell infiltration
[0651]
[0652]
[0653]
[0654] Table 3.3. Grading criteria for pulmonary arteriolar injury and inflammatory cell infiltration
[0655]
[0656]
[0657] Table 3.4. Histological characteristics of lung fibrosis scoring criteria
[0658]
[0659]
[0660] result:
[0661] a) All experimental rats showed no obvious abnormal physiological and behavioral changes during the experiment.
[0662] b) Experimental period. Except for the rats in Group 1, the body weight of all rats decreased slightly in the first 6 to 7 days after surgery. Then, the body weight of all rats began to gradually recover over the course of the experiment. There was no significant difference in body recovery between the CPD treatment group and the model group.
[0663] c) Changes in non-invasive lung function: The test parameters of lung function showed that TV, MV, respiratory rate and Penh changed little during the first week of unilateral lung fibrosis modeling. After treatment with FC-4, these test parameters did not show any significant changes in treated animals compared with vehicle-treated animals.
[0664] d) Pathological analysis of the left lung bronchioles and arterioles: The left lung histology showed obvious lung damage, and the damaged plates were clearly visible, which was manifested by varying degrees of bronchial hyperplasia, hyperplasia of epithelial cells in the terminal bronchioles and alveolar ducts, and different amounts of mucus in the bronchial lumen. There were varying degrees of inflammatory cell infiltration on the bronchial walls, especially in the adventitial area; and thick bronchial walls with granulomas were observed in some areas. Alveolar damage in the fibrotic core was manifested by alveolar epithelial shedding, regeneration, inflammatory cell infiltration of the alveolar wall, and fibrosis. Inflammatory exudates in the alveolar cavity accompanied by fibrotic masses were also widely identified. Varying degrees of arteriole endothelial cell shedding and hyperplasia were observed in the fibrotic core and fibrotic plates with varying degrees of inflammatory cell infiltration, most of which were located in the adventitial area ( Figure 1C and 1D FC-4 treatment at all doses had significant therapeutic effects in reducing bronchial and arteriolar damage in both the fibrotic core and fibrotic border (Table 3.7, Figure 1E and 1F ).
[0665] Table 3.7. Bronchial and arteriolar damage in the left lung
[0666]
[0667] Compared with the model group ***p<0.001; compared with the model group **p<0.01
[0668] e) Pathological analysis of the left lung fibrosis core: Masson's trichrome staining was used to score the left lung fibrosis according to the Ashcraft scoring method. Obvious alveolar damage with fibrosis ( Figure 1G The Ashcraft score data showed that fibrosis was significantly reduced after FC-4 treatment (Table 3.8, Figure 1H ). According to the Ashcraft scoring standard, the fibrosis score is divided into two parts, part I is a score ≤3, which means that the original alveolar structure is retained, accompanied by varying degrees of damage and fibrosis, and part II is scored ≥4, that is, the alveolar structure is partially or completely damaged, accompanied by varying degrees of damage and fibrosis. The data showed that in the model group, more than 60 percent (60%) of the Ashcraft scores were ≥4. About 80 percent (80%) of the Ashcraft scores of all drug treatment groups were ≤3. Statistical analysis showed that there was a significant difference between the FC-4 treatment group and the model group ( Figure 1J ).
[0669] Table 3.8. Assessment of left lung fibrosis
[0670]
[0671] Two-way ANOVA: ***p<0.001 compared with the model group
[0672] f) Pathological analysis of multiple biomarkers in the left lung fibrosis core: 1) Collagen I: For animals treated with FC-4, analysis of IHC staining in the fibrosis core showed a significant dose-dependent reduction in collagen I deposition, and showed significant differences in each dose treatment (p < 0.05) ( Figure 1J (I) and Figure 1K (I)); Collagen IV: Collagen IV IHC analysis showed that the deposition of collagen IV in the fibrotic core was significantly reduced in a dose-dependent manner in animals treated with FC-4 (p<0.05) ( Figure 1J (II) and Figure 1K (II)). 3) MMP-12: MMP-12 IHC analysis showed that in animals treated with FC-4, MMP-12 expression in the fibrotic core was significantly reduced, and there was a clear dose-dependent decrease (p>0.05) ( Figure 1J (III) and Figure 1K (III)). 4) TGF-β1: TGF-β1 IHC analysis showed that the expression of TGF-β1 in the fibrotic core was significantly reduced in animals treated with FC-4 (p<0.05) ( Figure 1J (IV) and Figure 1K (IV)). 5) Elastin: Elastin IHC analysis showed that the expression of elastin in the fibrotic core was significantly reduced in animals treated with FC-4 (p<0.05) ( Figure 1J (V) and Figure 1K (Group (V)).
[0673] Example 4: Study on the efficacy of MMP-12 inhibitors on the renal fibrosis model of SD rats with unilateral ureteral obstruction (UUO)
[0674] This study was designed to evaluate the therapeutic effect of the MMP-12 inhibitor FC-4 on the unilateral ureteral occlusion (UUO) model of renal fibrosis. Male Sprague-Dawley (SD) rats (180-220 g, n=71) were used in this study. The animals were randomly divided into 4 groups: vehicle group (Group 1, n=8), FC-4 2 mg / kg / day group (Group 2, n=9), FC-4 6 mg / kg / day group (Group 3, n=9), FC-4 20 mg / kg / day group (Group 4, n=9). The animals were anesthetized with 2.5% isoflurane inhalation. The left ureter was ligated to construct a unilateral ureteral occlusion (UUO) model and induce renal fibrosis. After modeling, the test article FC-4 was administered orally twice a day for 14 days. Peripheral blood serum was prepared before modeling and on day 15 (one day after the last administration). All animals were euthanized and processed for left renal pathology studies.
[0675] Treatment with FC-4 at a dose of 20 mg / kg / day slightly limited the increase in blood urea nitrogen (BUN) compared to the vehicle group, but all data did not show statistically significant differences compared to the model group. Serum creatinine levels did show similar changes to BUN.
[0676] Histologically, the left kidney showed significant morphological changes relative to UUO, including pelvic dilatation, renal medullary cortical atrophy, tubular epithelial cell flattening, tubular dilatation, inflammation, and necrosis. Interstitial fibrosis was clearly observed in the pelvic wall, medulla, and cortex. FC-4 treatment showed a clear dose-dependent effect, and the 20 mg / kg / day dose was more effective than the 2 mg / kg / day dose (p<0.01). Semiquantitative evaluation of cortical interstitial inflammation showed a significant reduction after FC-4 treatment, showing a dose-dependent effect of FC-4. Semiquantitative evaluation of cortical interstitial fibrosis showed that fibrosis scores were significantly reduced after FC-4 treatment in all dose groups. There was a clear dose-dependent effect in the FC-4 treatment group.
[0677] For animals treated with FC-4, immunohistochemical (IHC) staining analysis of the left renal cortical region showed a significant reduction in collagen I deposition at a dose of 20 mg / kg / day (p<0.001 for FC-4), with a dose-dependent decrease trend when treated with FC-4. It also showed a significant reduction in collagen IV deposition at a dose of 6 mg / kg / day (p<0.05) and 20 mg / kg / day (p<0.001) of FC-4, with a dose-dependent decrease trend.
[0678] In conclusion, UUO caused significant renal cortical damage, inflammation, and interstitial fibrosis within 15 days after modeling. Treatment with FC-4 had a significant dose-dependent effect on the limitation of renal damage, interstitial inflammation, or interstitial fibrosis. Analysis of fibrosis-related biomarkers showed that FC-4 treatment reduced the deposition of related collagens (collagens I and IV) in the cortical areas of damaged kidneys.
[0679] Detailed experimental methods
[0680] Animals: Sex: Male SD rats 180-220 g, 71 in total. Certificate: 11400700272659, Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., China. Animal husbandry: The animals were housed in a temperature-controlled environment with a 12-hour light / 12-hour dark cycle, with free access to food and water. Experimental procedures were performed in the animal research facility of KCI (Suzhou) Biotechnology Co., Ltd. (KCI) in accordance with IACUC guidelines. Model construction: A total of 36 male SD rats were used in this study. After anesthesia with 2.5% isoflurane inhalation, the abdomen of the animals was surgically opened. The left ureter was exposed and ligated near the bladder to construct the UUO model. After confirming the absence of bleeding, the abdominal wall was closed in layers. The animals were kept on a temperature-controlled mat (37°C) to recover from anesthesia, and then they were transferred to a cage with regular food and water.
[0681] Experimental grouping: UUO model animals were randomly divided into 4 groups, namely, vehicle group (Group 1, n = 9), FC-4 2mg / kg / day (Group 2, n = 9), FC-4 6mg / kg / day (Group 3, n = 9), FC-4 20mg / kg / day (Group 4, n = 9) (Table 4.1). Dosage regimen: All test articles were designed to be administered orally by gastric perfusion. The test article was designed to be administered twice a day starting on the same day of modeling for 14 days (Table 4.1). Endpoint: 1) Blood collection: Peripheral blood was collected from all animals in each group, and serum was prepared before modeling and on the 15th day (the first day after the last administration) and stored at -80°C. All animals were euthanized according to KCI SOP. After confirming the death of the animal without breathing and heartbeat, the left kidney was perfused with cold PBS, then perfused with 10% neutral formalin, and collected for further pathological studies. 2) Detection of serum BUN and creatinine: Serum BUN and creatinine levels were detected using a Hitachi 7060 fully automatic biochemical analyzer and related detection kits. 3) Renal pathological examination: 3a) Renal H&E staining and analysis: According to KCI's pathological SOP, all left kidneys were fixed with 10% formalin at room temperature for at least 24 hours. After fixation, the kidneys were cut longitudinally to obtain the maximum surface, dehydrated in gradient ethanol, cleaned in xylene, and embedded in paraffin. Thin sections (3-μm) were mounted on slides, dewaxed, rehydrated with distilled water, and stained with hematoxylin and eosin (H&E). All stained slides were scanned with a NanoZoomer digital pathology (S210, Hamamaci, Japan) scanner. A semiquantitative assessment of the degree of tubular epithelial flattening and dilation was graded from 0 to 5 based on the percentage of tubular involvement: score 0 = no damage; score 1 = 1-10% damage; score 2 = 10-25% damage; score 3 = 25-50% damage; score 4 = 50-75% damage; score 5 = 75-100% damage. A semiquantitative assessment of tubular necrosis was graded from 0 to 3 based on the percentage of tubular involvement: score 0 = no necrosis; score 1 = <25% necrosis; score 2 = 25-50% necrosis; score 3 = >50% necrosis. The average of tubular flattening, dilation, and necrosis was proposed as the total tubular injury. The semiquantitative assessment of interstitial inflammation was graded from 0 to 4 according to the degree of inflammatory cell infiltration: score 0 = no inflammatory cells; score 1 = mild inflammatory cell infiltration; score 2 = moderate inflammatory cell infiltration; score 3 = severe inflammatory cell infiltration; score 4 = massive inflammatory cell infiltration. 3b) Masson's trichrome staining and analysis of kidneys: Thin sections (3-μm) were mounted on slides, dewaxed, rehydrated with distilled water, and then stained with Masson's trichrome. All stained slides were scanned with a NanoZoomer digital pathology (S210, Hamamaci, Japan) scanner.Cortical interstitial fibrosis was semi-quantitatively evaluated at five different fields at x10 magnification randomly selected from the renal cortex, and the following scoring system was used to evaluate the percentage of interstitial fibrosis involvement from 0 to 4: score 0 = no fibrosis; score 1 = <10% fibrosis; score 2 = 10-25% fibrosis; score 3 = 25-75% fibrosis; score 4 = >75% fibrosis. 3c) Kidney IHC staining and analysis: All left kidneys from each group (eight right kidneys from the model group) were processed for biomarker analysis using IHC methods, such as collagen I (Abcam, Cat#ab34710), collagen IV (Abcam, Cat#ab6586). IHC staining was processed according to KCI's standard protocol for IHC. The stained slides were then scanned by Hamamatsu NanoZoomer Digital Pathology S210 slide scanner and analyzed using the software to obtain positive staining area / analysis area (%). 4) Statistical analysis: All statistical analyses were performed using Graphpad, Prism 5.0, and p values < 0.05 were considered significant. All data were reported as mean ± SEM. Differences between groups were determined using ANOVA with Bonferroni test or Student's T test.
[0682] Table 4.1: Animal experimental groups
[0683] Group N OP CPD Solubility Mg / mL Dose mL / kg Dosage mg / kg Group 1 9 UUO solvent N / A 10 N / A Group 2 9 UUO FC-4 0.1mg / ml 10 2 mg / kg / day, twice a day Group 3 9 UUO FC-4 0.3mg / ml 10 6 mg / kg / day, twice a day Group 4 9 UUO FC-4 1mg / ml 10 20 mg / kg / day, twice a day
[0684] result:
[0685] a) Physiological changes of animals during the experiment: Several animals died during the experiment, which was considered to be a modeling failure, such as ureteral rupture during surgery leading to peritonitis.
[0686] b) Changes in serum BUN and creatine: Serum BUN increased in all animals on day 15 after UUO compared with before modeling (p<0.001). Treatment with FC-4 at a dose of 20 mg / kg / day slightly limited the increase in BUN compared with the vehicle group, but none showed statistically significant differences compared with the model group. Serum creatinine levels did show similar changes as BUN ( Figure 2B ).
[0687] c) Changes in left kidney damage - renal tubular damage: After 15 days of UUO, the left kidney of all animals showed pelvic dilatation. The renal cortex showed obvious atrophy, accompanied by varying degrees of flattening of tubular epithelial cells, tubular dilatation and interstitial inflammatory cell infiltration, and few tubular necrosis foci ( Figure 2C FC-4 treatment showed a significant dose-dependent effect, and the dose of 20 mg / kg / d was more effective than the dose of 2 mg / kg / d (p<0.01)( Figure 2D (I)).
[0688] d) Changes in left kidney injury - interstitial inflammation: Semi-quantitative evaluation of cortical interstitial inflammation showed that cortical interstitial inflammation was significantly reduced after FC-4 treatment, and the effect was dose-dependent ( Figure 2D (II)).
[0689] e) Changes in left kidney lesions - cortical interstitial fibrosis: After 15 days of UUO, the left kidney showed significant interstitial fibrosis in the pelvic cavity, medullary region, and cortical region in all animals. Interstitial fibrosis in the cortical region was analyzed and, with the treatment of the tested CPD, showed different degrees of fibrosis ( Figure 2E Semi-quantitative evaluation of cortical interstitial fibrosis showed that treatment with FC-4 at a dose of 20 mg / kg / day significantly reduced the fibrosis score (p<0.001). There was a clear dose-dependent effect in the FC-4 treatment group ( Figure 2F ).
[0690] f) Pathological analysis of multiple biomarkers in the left kidney: Collagen I: For animals treated with FC-4, IHC staining analysis of the left renal cortical region showed that collagen I deposition was significantly reduced at a dose of 20 mg / kg / day (p<0.05), and there was a dose-dependent decrease in the presence of FC-4 ( Figure 2G (I) and Figure 2H (I)). Collagen IV: For animals treated with FC-4, IHC staining of the left renal cortex region showed that collagen I deposition was significantly reduced at a dose of 20 mg / kg / day (p<0.001), showing a dose-dependent decrease ( Figure 2G (II) and Figure 2H (I)).
[0691] References
[0692] 1. US 7179831
[0693] 2. WO 02 / 096426
[0694] 3. US 2004 / 0067996
[0695] 4. WO 2004 / 108086
[0696] 5. WO 02 / 074752
[0697] 6. WO 2004 / 020415
Claims
1. Compound of formula (III): or a tautomer or a pharmaceutically acceptable salt thereof, in: Ring D is pyridyl; X is S; Y is selected from the group consisting of O, CH2 or NH; R1 is hydrogen or C 1-4 alkyl; R2 is selected from the group consisting of hydrogen, -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2; R3 is selected from hydrogen; R4 is hydrogen; R5 is hydrogen; R7 is hydrogen; and n is 1.
2. The compound according to claim 1, characterized in that X is S, and Y is O.
3. The compound according to claim 1, characterized in that n is 1; and R2 is -CH3, C 1-4 Alkoxy or -C(O)NH2.
4. Compounds of formula (IV): or a tautomer or a pharmaceutically acceptable salt thereof, in: R1 is hydrogen or C 1-4 alkyl; R2 is selected from the following group: -CH3, C 1-4 Alkoxy, -OH, -CH2OH or -C(O)NH2; R4 and R5 are each hydrogen; and R7 is hydrogen.
5. The compound according to claim 4, characterized in that R2 is -CH3, C 1-4 Alkoxy or -C(O)NH2.
6. The compound according to claim 4, characterized in that R1 is C 1-4 alkyl.
7. The compound according to claim 1, which is a compound selected from the group consisting of: or a tautomer or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 7 or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 8 and at least one pharmaceutically acceptable carrier.
10. Use of the pharmaceutical composition according to claim 9 in the preparation of a drug for inhibiting macrophage elastase MMP-12.
11. Use of the pharmaceutical composition of claim 9 in the preparation of a medicament for treating a disease mediated by macrophage elastase MMP-12, wherein: The disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, non-alcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome and nephritis.
